

PATENT APPLICATION
DOCKET NO. DFCI-522A

A

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

PATENTS, TRADEMARKS, COPYRIGHTS AND LITIGATION

MUNROE H. HAMILTON
(1906-1984)

CAROLYN S. ELMORE
SUPERVISING PATENT AGENT

OF COUNSEL

RICHARD A. WISE
SUSAN G. L. GLOVSKY
DAVID J. THIBODEAU, JR.

BARRY W. CHAPIN
PATENT AGENT

TECHNICAL SPECIALISTS

SUSAN M. ABELLEIRA
SANDRA A. BROCKMAN
THERESA A. DEVLIN
ANTOINETTE GIULIANO
EDGAR W. HARLAN
KENYON SCHUETT

JOHN W. MEDBURY
ADMINISTRATIVE DIRECTOR

BARBARA J. FORGUE
ADMINISTRATOR OF PATENT
AND TRADEMARK PRACTICE

DAVID E. BROOK
JAMES M. SMITH
LEO R. REYNOLDS
PATRICIA GRANAHAN
JOHN L. DUPRÉ
DAVID J. BRODY
MARY LOU WAKIMURA
THOMAS O. HOOVER
ALICE O. CARROLL
SCOTT PIERCE
MILLEN E. WENDLER
JEROLD M. BLUHM
RAYMOND I. BRUTTOMESSO, JR.
ANN J. COLLINS
ROBERT T. CONWAY
STEVEN G. DAVIS
CAROL A. EGNER
DOREEN M. HOGLE
J. GRANT HUSTON
DAVID E. HUANG
RODNEY D. JOHNSON
HELEN LEE
ELIZABETH W. MATA
TIMOTHY J. MEAGHER
NINA L. PEARLMUTTER
DEIRDRE E. SANDERS
ROBERT J. SAYRE
RICHARD W. WAGNER
LISA M. WARREN
DARRELL L. WONG
*NOT ADMITTED IN MASS

Assistant Commissioner for Patents
Washington, D.C. 20231

Date: October 9, 1997

EXPRESS MAIL LABEL NO. EM 361196998 US

Sir:

Transmitted herewith for filing under the provisions of 37 C.F.R § 1.53(b)(1) is a
 Continuation-in-Part Continuation Divisional application of prior application
Serial No. 08/802,474 filed February 18, 1997 in which a processing and Retention Fee
are being paid pursuant to the provisions of 37 C.F.R. 1.53 (d)(1).
The teachings of the above application are incorporated herein by reference in their
entirety.

Inventor(s): Ellis Reinhertz, Linda Clayton, Timothy D. Ocain and Raymond J. Patch

Title: THYMOCYTE CASPASE ACTIVITY AND NEGATIVE SELECTION

Specification, Claims, Abstract of the Disclosure

5 sheets of ~~XXXXXX~~/informal drawings. (Figs. 1, 2A-2D, 3, 4A-4F)

An assignment of the invention to _____

A Verified Statement to establish Small Entity Status under 37 C.F.R. 1.9 and
37 C.F.R. 1.27 is enclosed.

A Verified Statement of Small Entity Status was filed in the prior application on
_____.

~~XXXXXX~~ Unexecuted Combined Declaration/Power of Attorney.

Other: _____

The filing fee has been calculated as shown below:

(Col. 1)	(Col. 2)	
FOR	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	52 - 20 =	* 32
INDEP CLAIMS	2 - 3 =	** 0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED		

*not fewer than 20

**not fewer than 3

SMALL ENTITY

RATE	Fee
	\$ 395
X \$11=	\$
X \$41=	\$
+ \$135=	\$
Assignment Fee	\$
Total:	\$

OTHER THAN A
SMALL ENTITY

RATE	Fee
	\$ 790
X \$22=	\$ 704
X \$82=	\$ 0
+ \$270=	\$
Assignment Fee	\$
Total:	\$ 1,494

Please charge my Deposit Account No. 08-0380 in the amount of \$ _____

A check in the amount of \$ _____ to cover the filing fee is enclosed.

Priority of application Serial No. _____ filed on _____ in
_____ is claimed under 35 U.S.C. 119.
(country)

The certified copy has been filed in prior application Serial No. _____
filed _____.

Authorization is hereby granted to charge payment of any additional
fees associated with this communication, including any fees under
37 CFR 1.16 or under 37 CFR 1.17, or credit any overpayment to Deposit Account
No. 08-0380. A copy of this letter is enclosed for accounting purposes.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Lisa M. Warren
Lisa M. Warren

Registration No. 41,368

Attorney for Applicant(s)

Telephone (781) 861-6240

Faxsimile (781) 861-9540

Dated: October 9, 1997

Date: 10/9/97 Express Mail Label No. EM361196998US

Inventors: Ellis Reinhertz, Linda Clayton,
Timothy D. Ocain and Raymond J.
Patch
Attorney's Docket No.: DFCI-522A

THYMOCYTE CASPASE ACTIVITY AND NEGATIVE SELECTION

RELATED APPLICATION

This application is a continuation of U.S. application Serial No. 08/802,474, filed February 18, 1997. The 5 teachings of this prior application are incorporated herein by reference in their entirety.

GOVERNMENT FUNDING

Work described herein was supported by an award from the Mathers Foundation and by National Institutes of Health 10 grants AI19807, DK43551 and DK47677 and ES08111. The United States government may have certain rights in the invention.

BACKGROUND OF THE INVENTION

The T cell repertoire is generated through a tightly 15 regulated developmental program of selection or "filtering" in which thymocytes bearing immunologically desirable T cell receptor (TCR) specificities are preserved and those expressing harmful specificities are eliminated (reviewed in Fowlkes and Pardoll, *Adv. Immunol.* 44:207-264 (1989)). 20 T-lineage cells expressing autoreactive TCRs are deleted in the thymus via a process termed negative selection (reviewed in Nossal, *Cell* 76:229-239 (1994)). Multiple lines of evidence utilizing both normal and transgenic mice

show that this negative selection process occurs during a restricted stage(s) of thymic differentiation (Fowlkes and Pardoll, *Adv. Immunol.* 44:207-264 (1989); Fowlkes et al., *Nature* 334:620-623 (1988); Kisielow et al., *Nature* 333:742-746 (1988); Murphy et al., *Science* 250:1720-1723 (1990); Vasquez et al., *J. Exp. Med.* 175:1307-1316 (1992); Sebzda et al., *Science* 263:1615-1618 (1994)). The deletion process requires TCR recognition of antigenic peptides displayed on antigen presenting cells in complex with major histocompatibility complex (MHC) class I or class II molecules, and generally involves thymocytes at the double positive (DP) stage of development.

Although the mechanism of negative selection is unknown, the targeted thymocytes die via apoptosis (Murphy et al., *Science* 250:1720-1723 (1990)), a physiologically controlled form of cell death utilized by metazoan organisms during normal development, as well as for homeostasis (reviewed in Steller, *Science* 267:1445-1449 (1995); Vaux, *Proc. Natl. Acad. Sci. USA* 90:86-789 (1993); Vaux and Strasser, *Proc. Natl. Acad. Sci. USA* 93:2239-2244 (1996)). Apoptosis occurs as a consequence of extracellular signalling events such as crosslinking of certain receptors, including CD95 (Trauth et al., *Science* 245:301-305 (1989); Yonehara et al., *J. Exp. Med.* 169:1747-1756 (1988); Itoh and Nagata, *J. Biol. Chem.* 268:10932-10937 (1993); Alderson et al., *Intl. Immunol.* 6:1799-1806 (1994); Takahashi et al., *Cell* 76:969-976 (1994)), TNF receptors (Tartaglia et al., *Cell* 74:845-853 (1993)) and a recently identified Death Receptor 3 (DR3) (Chinnaiyan et al., *Science* 274:990-992 (1996a)) or as a result of growth factor withdrawal (reviewed in Yang and Korsmeyer, *Blood* 88:386-401 (1996)). Upon induction of apoptosis, cells undergo a morphologically characteristic

process of nuclear condensation, blebbing of cellular membranes and disintegration into small fragments which are removed by phagocytes (reviewed in Steller, *Science* 267:1445-1449 (1995); Vaux, *Proc. Natl. Acad. Sci. USA* 90:86-789 (1993); Vaux and Strasser, *Proc. Natl. Acad. Sci. USA* 93:2239-2244 (1996)).

SUMMARY OF THE INVENTION

T cell receptors (TCRs) are created by a stochastic gene rearrangement process during thymocyte development, generating thymocytes bearing useful as well as unwanted specificities. Within the latter group, autoreactive thymocytes arise which are subsequently eliminated via a thymocyte-specific apoptotic mechanism, termed negative selection. The molecular basis of this deletion was heretofore unknown.

Work described herein shows that TCR triggering by peptide/MHC ligands activates a caspase in double positive (DP) CD4+CD8+ thymocytes, resulting in their death. Inhibition of this enzymatic activity prevents antigen-induced death of DP thymocytes in fetal thymic organ culture (FTOC) from TCR transgenic mice, as well as apoptosis induced by anti-CD3 ϵ monoclonal antibody and corticosteroids in FTOC of normal C57BL/6 mice. Hence, a common enzyme mediates immature thymocyte susceptibility to cell death.

Accordingly, this invention pertains to an isolated caspase or procaspsase expressed in immature thymocytes, or an active derivative or fragment thereof, wherein said caspase is necessary for apoptosis. The caspase is characterized by its ability to be triggered by TCR stimulation with peptide/MHC, anti-CD3 ϵ or other anti-TCR-specific monoclonal antibody, or corticosteroids in

thymocytes. In one embodiment, the caspase is a fragment having caspase activity, e.g., binding or enzymatic activity. In another embodiment, the caspase or procaspsase is a derivative possessing substantial sequence identity 5 with the endogenous caspase or procaspsase. In particular embodiments, the caspase or procaspsase is purified to homogeneity or is substantially free of other thymocyte proteins.

The invention also pertains to an isolated nucleic acid molecule which encodes a caspase or procaspsase expressed immature thymocytes and necessary for apoptosis, or an active derivative or fragment thereof. In one embodiment, the encoded caspase is a fragment having caspase activity. In another embodiment, the encoded 15 caspase or procaspsase is a derivative possessing substantial sequence identity with the endogenous caspase or procaspsase. In particular embodiments, the isolated nucleic acid molecule encodes a caspase or procaspsase with the same amino acid sequence as the endogenous caspase or procaspsase. In another embodiment, the isolated nucleic acid molecule has the same nucleotide sequence as the 20 endogenous gene encoding the caspase or procaspsase.

The invention also relates to DNA constructs comprising the nucleic acid molecules described above 25 operatively linked to a regulatory sequence, and to recombinant host cells, such as bacterial cells, fungal cells, plant cells, insect cells and mammalian cells, comprising the nucleic acid molecules described above operatively linked to a regulatory sequence. The invention 30 also pertains to an antibody, or an antigen-binding fragment thereof, which selectively binds to the caspase or procaspsase, or an active derivative or fragment thereof; in a particular embodiment, the antibody is a monoclonal

antibody. The invention also relates to a method for assaying the presence of a caspase or procaspase, present in immature thymocytes and necessary for apoptosis, in a cell, e.g., in a tissue sample, comprising contacting said 5 cell with an antibody which specifically binds to the caspase or procaspase.

The invention further relates to methods of inhibiting apoptosis in a lymphocyte population, particularly in immature thymocytes, comprising contacting the lymphocyte 10 population with an agent which inhibits the activity of the caspase, such as in administering to a subject an agent which inhibits the activity of the caspase. For example, the invention also pertains to methods of enhancing an immune response against an antigen in a subject by 15 administering to the subject an effective amount of an agent which inhibits the activity of the caspase along with the selected antigen. In a particular embodiment, the antigen is a cancer antigen.

The present invention also relates to an assay for 20 identifying agents which alter the activity of the caspase implicated in lymphocyte, particularly thymocyte, apoptosis. For example, the caspase, or an active fragment or derivative thereof, can be contacted with a caspase substrate in the presence of an agent to be tested, and the 25 level of lymphocyte apoptosis can be assessed.

By inhibiting apoptosis as described above, the down regulation and/or deletion of lymphocytes, particularly thymocytes, can be prevented or inhibited; thus, DP thymocytes are prevented from self-destruction. This 30 results in a T cell receptor population with an increased proportion of autoreactive T cells; that is, there is an increased occurrence of T cells which have specificity for the host animal's own cells. This is particularly

advantageous when it is desirable to generate an immune response against the host's own cells (an autoimmune response), such as, for example, in the case of tumor growth and cancers such as leukemia and melanomas. This
5 technology is especially useful for preparing animal models having depleted T cell populations and animal models for autoimmune disease.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates structures of the peptide-based
10 caspase inhibitors and related compounds. The structures of the peptide-based inhibitor analogues used in these studies are shown along with their molecular weight as verified by mass spectrometry. The common names of the compounds are also given.

Figures 2A-2D show the results of Western blot analysis, which reveal antigen-induced activation of a thymic caspase. Arrows indicate the position of the activated thymic caspase subunit which binds the biotin-DEVDamk. Figure 2A shows the results when thymic
15 extracts, prepared from PBS, VSV8 or SEV9 injected N15 tg RAG-2^{-/-} H-2^b mice, were incubated 15 minutes with (+) or without (-) 2 mM biotin-DEVDamk. Each lane contained thymic extract equivalent to 2 million thymocytes. VSV8 peptide injections were performed 1.5 hours prior to
20 harvest. Figure 2B shows the results when 140 ng of purified, recombinant Mch2a and 3.5 ng of purified, recombinant Yama were incubated for 15 minutes with 2 mM biotin-DEVDamk. Figure 2C shows the results when thymic extracts, prepared from mice 2 hours after VSV8 peptide
25 injection, were incubated 15 minutes with 2 mM biotin-DEVDamk alone, 2 mM zVADfmk alone, or preincubated 15 minutes with an excess of 1000x, 500x, 100x, 10x or an

equal concentration of zVADfmk. Figure 2D shows the results when thymic extracts, isolated from mice 2 hours after VSV8 peptide injection, were incubated for 15 minutes with 2 mM biotin-DEVDamk alone (-), or, alternatively, 5 incubated for 15 minutes with 200 μ M zVADfmk or zVADmk and then biotin-DEVDamk added to 2 mM for another 15 minutes.

Figure 3 illustrates a model of TCR regulated activation of thymic caspase, particularly a schematic model of the process by which peptide/MHC (pMHC) on an 10 antigen presenting cell (stromal cell) triggers the TCR of an immature DP thymocyte, resulting in the activation of a caspase, cleavage of thymocyte protein substrates and thymocyte apoptosis. Note that selective engagement of the CD8 co-receptor with the TCR and pMHC is shown, consistent 15 with a class I restricted TCR such as N15; in the case of a class II restricted TCR, CD4 rather than CD8 would be engaged. The large arrow indicates that TCR mediated signal transduction results in cleavage of procaspase to the active caspase tetramer. The tetramer then cleaves 20 certain cellular substrates, resulting in negative selection.

Figures 4A-4F illustrate that a caspase inhibitor blocks peptide/MHC-induced deletion of DP thymocytes. FACS analysis of FTOC from N15 TCRtg RAG-2^{-/-}H-2^b mice following 25 18 hour treatment with no addition (4A); addition of 10 μ M VSV8 peptide (4B); 2 hours with 100 μ M zVADfmk followed by 18 hours with 10 μ M VSV8 (4C); 2 hours with 100 μ M zVADmk followed by 18 hours with 10 μ M VSV8 (4D); 2 hours with 0.25% DMSO followed by 18 hours with 10 μ M VSV8 (4E); and 30 18 hours with 10 μ M SEV9 (4F). The numbers within the quadrants represent the percent of cells in that quadrant.

DETAILED DESCRIPTION OF THE INVENTION

The T cell repertoire is generated through a tightly regulated developmental program of selection or "filtering", in which thymocytes bearing immunologically desirable TCR specificities are preserved and those expressing harmful specificities are eliminated (reviewed in Fowlkes and Pardoll (1989)). T-lineage cells expressing autoreactive TCRs are deleted in the thymus via a process termed negative selection (reviewed in Nossal (1994)).

10 Although the mechanism of negative selection is unknown, the targeted thymocytes die via apoptosis (Murphy et al. (1990)), a physiologically controlled form of cell death utilized by metazoan organisms during normal development as well as for homeostasis (reviewed in Steller (1995); Vaux 15 (1993); Vaux & Strasser (1996)).

Recent analyses of the death pathways in various systems have begun to delineate the biochemical basis of apoptosis. Particularly, activation of interleukin 1 converting enzyme-like (ICE-like) cysteine proteases (now termed caspases) has proven to be a hallmark of apoptotic death (reviewed in Nalin, *Structure* 3:143-145 (1995); Henkart, *Immunity* 4:195-201 (1996)). There are presently ten human homologues of the *ced 3* cysteine protease first defined by genetic analysis of cell death in *Caenorhabditis elegans* (Alnemri et al., *Cell* 87:171 (1996); Muzio et al., *Cell* 85:817-827 (1996); Duan et al., *J. Biol. Chem.* 271:16720-16724 (1996a); Fernandes-Alnemri et al., *Proc. Natl. Acad. Sci. USA* 93:7464-7469 (1996)). These enzymes exist as inactive proenzymes which become active when 30 cleaved to subunits of ~17-20 kd and ~10-12 kd.

The molecular structures of ICE (caspase-1) and Yama (caspase-3) have been determined (Walker et al., *Cell* 78:343-352 (1994); Wilson et al., *Nature* 370:270-275

(1994); Rotonda *et al.*, *Nature Struct. Biol.* 3:619-625 (1996)). The active enzymes exist as tetramers made up of two large and two small subunits. Comparison of these structures suggests that the caspase family falls into two major groups: those that most resemble caspase-1, and those that most resemble caspase-3 (and also ced-3). The substrate binding pockets of these two groups have distinct differences pointing to potentially unique substrate specificities. The active sites contain a critical cysteine within the canonical pentapeptide, QACR/QG (SEQ ID NO: 1), and R and Q residues (Arg 179, Gln 283 and Arg 341, for example, in caspase 3) conserved among all caspase family members. A unique characteristic of these enzymes is that they cleave after an aspartic acid residue in their substrate (Sleath *et al.*, *J. Biol. Chem.* 265:14526-14528 (1990); Howard *et al.*, *J. Immunol.* 147:2964-2969 (1991); Thornberry *et al.*, *Biochemistry* 33:3934-3940 (1994)). Thus, the fact that activation of these enzymes occurs by cleavage at aspartic acid residues suggests both autocatalytic capabilities and the possibility of a cascade of various cysteine proteases, with one family member activating others during apoptosis.

To date, the characterization of caspase enzymatic activities has typically been investigated using transfected cell lines. Hence, the physiological roles of most of these cysteine proteases *in vivo* are unclear. Two cysteine proteases, caspase-3 and ICE-LAP3 (caspase-7), have been shown to be proteolytically activated by apoptotic stimuli, implying a central role for this family of enzymes in cell death *in vivo* (Chinnaiyan *et al.*, *J. Biol. Chem.* 271:4961-4965 (1996b); Duan *et al.*, *J. Biol. Chem.* 271:1621-1625 (1996b); Schlegel *et al.*, *J. Biol. Chem.* 271:1841-1844 (1996)).

Given the link between apoptosis and negative selection in the thymus, work described herein examines the potential role of caspase activity in antigen-triggered deletion of CD4+CD8+ double positive (DP) fetal and adult thymocytes. Using peptide-based enzyme substrates, it is shown herein that TCR ligation by peptide/MHC activates a procaspase in DP thymocytes, which then causes cell death; specific enzyme inhibitors block this death process. These findings provide the molecular basis for negative selection.

Caspases are irreversibly inhibited by tri- or tetrapeptide sequences (VAD, YVAD (SEQ ID NO: 2) and/or DEVD (SEQ ID NO: 3)) linked to a chemical moiety such as fluoromethylketone (fmk) or various acyloxymethylketones (amk) which covalently modify the enzyme, thereby inactivating its catalytic function (Chapman, K.T., *Bioorg. Med. Chem. Lett.* 2:613-618 (1992); Thornberry et al., et al., *Nature* 356:768-774 (1992); Thornberry et al., *Biochemistry* 33:3934-3940 (1994); Rotonda et al., *Nature Struct. Biol.* 3:619-625 (1996)). The peptide-based inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVADfmk), blocks the induction of apoptosis induced by expression of REAPER protein when added to *Drosophila* Schneider cells (Pronk et al., *Science* 271:808-810 (1996)); such experiments demonstrate that REAPER-induced apoptosis requires activation of a caspase.

In order to analyze the effect of inhibition of members of the caspase family of cysteine proteases on negative selection in the thymus, a fetal thymocyte organ culture (FTOC) system was utilized in the work described herein. FTOC was chosen over both *in vivo* whole animal studies or *in vitro* cell suspension cultures for several

reasons. First, FTOC allows analysis of the effects of pharmaceutical agents on thymocyte development in a system which more closely mimics *in vivo* conditions than does thymocyte suspension culture. Second, pharmacophores which 5 cannot be utilized in whole mice, either due to systemic toxicity or limitations in their bioavailability, can be assayed easily in FTOC. Furthermore, the relatively small volumes required minimize the amount of necessary chemical.

As work described herein demonstrates, peptide/MHC-induced negative selection of DP thymocytes involves the activation of a thymic caspase. Double staining with anti-CD4 mAb and N-(biotinylaspartylglutamylvalinyl)aspartic acid [(2,6-dimethylbenzoyl)oxy]methyl ketone (biotin-DEVDamk) (a 15 biotinylated substrate of cysteine proteases) of thymic sections from both fetal and adult N15 TCRtg RAG-2^{-/-} H-2^b mice demonstrates that the caspase is activated in the DP thymocyte subpopulation within a time frame of ≤2 hours. Subsequently, at 4 hours, a tremendous increase in the 20 number of apoptotic thymocytes was observed, as determined by TUNEL assays of histological sections of thymuses. At 18 hours, by FACS analysis and immunohistological analysis, >90% of the DP thymocyte population is deleted. Both the disappearance of DP thymocytes and the increase in numbers 25 of apoptotic cells in histological sections are blocked by treatment of FTOC with zVADfmk, a peptide-based inhibitor of cysteine proteases.

Biochemical analysis of thymic lysates prepared from adult N15 TCRtg RAG-2^{-/-} H-2^b mice using biotin-DEVDamk 30 confirms the induction of an active caspase within 2 hours after tail vein injection of VSV8 antigen (RGYVYQGL). This enzyme activation is specifically induced, as it is not activated in control (PBS) or animals treated with the

irrelevant Sendai virus-derived peptide (FAPGNYPAL; SEQ ID NO: 4) (SEV9). Pretreatment of the thymic lysates with an excess of the irreversible inhibitor zVADfmk prevents binding of the biotin-DEVDamk to the caspase, while the 5 chemically-related control compound zVADmk, a compound identical to zVADfmk (Figure 1) except for the absence of the fluoride atom which is required for the irreversible inhibition of caspases, does not. zVADmk also has no effect on antigen-induced depletion of DP thymocytes in 10 FTOC or the appearance of TUNEL positive cells in histological sections upon VSV8 peptide treatment of FTOC. Thus, the zVADfmk which blocks depletion of DP thymocytes in FTOC also blocks binding of the biotin-DEVDamk to its substrate. These results support the conclusion that the 15 caspase functionally inhibited by zVADfmk in FTOC is the same as that detected by biotin-DEVDamk by Western blot analysis. Activation of this caspase is the molecular basis for negative selection of DP thymocytes.

The above data can be schematically represented as 20 shown in Figure 3. The TCR of the double positive thymocyte binds the peptide/MHC (pMHC) on an antigen presenting stromal cell with the restricted association of the CD4 or CD8 co-receptor; in the case of the N15 TCR transgenic mouse, the CD8 co-receptor is involved. If the 25 affinity of the TCR/peptide/MHC interaction is of sufficient magnitude, as is true for the N15 TCR and VSV8/K^b complex (pMHC), the thymocyte is triggered to undergo negative selection. Upon this triggering, a procaspase is cleaved to form an active tetramer which 30 catabolizes cellular substrates, resulting in apoptosis of the DP thymocyte. It is reasonable that a similar mechanism is operative via B cell receptors in early B cell development, and, thus, the methods described herein are

applicable to both B lymphocytes and T lymphocytes (Nossal, *Cell* 76:229-239 (1994)).

Analysis of the Western blots demonstrates that there is likely only one enzyme activated, since there is a single predominant band by gel analysis. A less intense band migrating slightly faster than the major band may be a degradation product or post-translational modification. However, the possibility that a second caspase might be activated cannot be excluded. If the latter is the case, then both enzymes are blocked by the zVADfmk inhibitor.

Studies to date defining substrates and inhibitors of known caspases offer additional insights into the possible identity of the thymic caspase. Peptide-based inhibitors serve to characterize different substrate specificities among the caspase family members. The tetrapeptide aldehyde Ac-YVAD-CHO inhibits caspase-1 at ~10,000-fold lower concentration than that required to inhibit caspase-3. In contrast, Ac-DEVD-CHO inhibits caspase-3 49 times better than caspase-1 (Rotonda *et al.*, *Nature Struct. Biol.* 3:619-625 (1996)).

Utilizing thymic lysates from VSV8-injected N15 TCRTg RAG^{-/-} H-2^b mice, biotin-YVADamk failed to detect the caspase readily revealed by biotin-DEVDamk. The recombinant caspase-3 protein used as a positive control was detected by biotin-YVADamk only when 100 times more of the enzyme was used. The crystal co-complex structures of caspase-1 and caspase-3 and their inhibitors clarify the observed substrate specificities (Walker *et al.*, *Cell* 78:343-352 (1994); Wilson *et al.*, *Nature* 370:270-275 (1994); Rotonda *et al.*, *Nature Struct. Biol.* 3:619-625 (1996)): the S4 subsite in caspase-1 is a hydrophobic depression into which a tyrosine residue fits nicely as in the ac-YVAD-CHO peptide aldehyde inhibitor. In contrast,

the comparable S4 subsite in caspase-3 forms a narrow pocket fitting tightly around an aspartic acid residue as in the ac-DEVD-CHO peptide aldehyde inhibitor. This substrate difference suggests that the thymic caspase 5 should be grouped with the caspase-3-like cysteine proteases rather than the caspase-1-like.

Studies with proteins which inhibit functional enzymatic activity further serve to categorize the caspase family members. *Bcl-2*, first identified as a 10 proto-oncogene in B-cell follicular lymphomas, inhibits some forms of apoptotic cell death including death induced by *ICH-1* (caspase-2) (reviewed in Yang and Korsmeyer, *Blood* 88:386-401 (1996)). The cytokine response modifier, *crmA*, derived from the cowpox virus, inhibits caspase-1 but not 15 caspase-2. At high concentrations, however, *crmA* also inhibits caspase-3 (Nicholson et al., *Nature* 376:37-43 (1995); Tewari et al., *Cell* 81:801-809 (1995)). Negative selection is unaffected in *Bcl-2* (Sentman et al., *Cell* 67:879-888 (1991)) and caspase-1 (Li et al., *Cell* 20 80:401-411 (1995); Kuida et al., *Science* 267:2000-2003 (1995)) knockout animals. The *crmA* transgenic mouse in which *crmA* is directed to the T-cell compartment via a CD2 enhancer demonstrates a phenotype in which CD95-induced peripheral T cell apoptosis is inhibited, but negative 25 selection in the thymus appears to be unaffected (Smith et al., *EMBO J.* 15:5167-5176 (1996)). The inhibitors *Bcl-2* and *crmA* have complementary effects in that the *crmA* transgene does not affect γ -irradiation or dexamethasone-induced apoptosis, while *Bcl-2* inhibits both. 30 Neither *Bcl-2* nor *crmA* transgenes, however, affect negative selection. One would expect that the thymic caspase described here would not be inhibited by *crmA* or by *Bcl-2*.

Analysis of apoptotic pathways triggered by different stimuli in cells transfected with *Bcl-2* and *crmA* have been used to suggest molecular ordering of particular caspases within death pathways, and further imply the presence of a cascade of caspases with one member activating others.

Studies suggest a molecular ordering in which *Bcl-2* and *Bcl-x_L*, a homologue of *Bcl-2*, function upstream of caspase-3 and caspase-7 (Chinnaiyan *et al.*, *J. Biol. Chem.* 271:4373-4576 (1996c)); *crmA* also appears to function by inhibiting a protease upstream of caspase-3 and caspase-7, but in a different pathway from that inhibited by *Bcl-2* (Chinnaiyan *et al.*, *J. Biol. Chem.* 271:4373-4576 (1996c)).

Granzyme B is a serine protease which cleaves at an aspartic acid in its substrate (Caputo *et al.*, *Nature Struct. Biol.* 1:364-367 (1994)) and is activated only in cytolytic T lymphocytes (Hanson and Ley, *Mol. Cell. Biol.* 10:5655-5662 (1990); Hanson *et al.*, *J. Biol. Chem.* 266:24433-24438 (1991); Heusel *et al.*, *J. Biol. Chem.* 266:6152-6158 (1991)). Post-activation, granzyme B is transferred into target cells, where it initiates caspase cleavage, notably of caspase-3 (Darmon *et al.*, *Nature* 377:446-448 (1995); Quan *et al.*, *Proc. Natl. Acad. Sci. USA* 93:1972-1976 (1996)). Thus, proteases other than caspases may activate these enzymes, initiating the cascade of caspase functional programs leading to cell death. *ICH-3* has also been shown to be activated by granzyme B (Wang *et al.*, *J. Biol. Chem.* 271:20580-20587 (1996)). Ordering of *ICH-3* activity places it upstream of caspase-1 in the granzyme B pathway, and upstream of caspase-3 as well.

Certain cysteine proteases have been analyzed by targeted gene disruption. Caspase-1 knockout animals do not have a generalized death defect, suggesting that this enzyme may not be central to all death pathways (Li *et al.*,

Cell 80:401-411 (1995); Kuida *et al.*, *Science* 267:2000-2003 (1995)). The CD95-induced death pathway is affected in these animals, but negative selection is not altered in *mlr* mice bearing the spontaneous CD95 mutation (reviewed by

5 Rozzo *et al.*, *Sem. in Immunol.* 6:19-26 (1994)). *ICH-1* and *ICH-3* mouse cysteine proteases have also been knocked out; mAb induced-depletion of DP thymocytes appears to proceed normally in these animals, suggesting that neither of these proteases is the caspase important in thymic selection.

10 Furthermore, cleavage of poly(ADP-ribose) polymerase (PARP) in thymic lysates of C57BL/6 animals injected intraperitoneally with anti-CD3 ϵ mAb was not observed (data not shown). Since PARP is a substrate of caspase-3, this suggests that caspase-3 is also not responsible for the 15 observed thymic apoptosis. Assuming that the *crmA* levels were sufficiently high in the *crmA* transgenic mice described above (Smith *et al.*, *EMBO J.* 15:5167-5176 (1996)), then caspase-3 would have been inhibited in those mice, and yet negative selection was unaffected. The 20 absence of an effect on thymopoiesis in caspase-3 knockout mice is also consistent with this notion. These studies suggest that the thymic caspase is not caspase-1, caspase-3, *ICH-1* or *ICH-3*.

Western blots demonstrate that there is likely only 25 one enzyme activated, since there is a single predominant band by gel analysis. A less intense band migrating slightly faster than the major band may be a degradation product or post-translational modification. Either or both of these bands can be isolated and purified by HPLC, and 30 the resulting purified protein can be sequenced. Alternatively, the purified protein can be enzymatically digested by methods known in the art to produce peptide fragments which can be sequenced. The sequencing can be

performed, for example, by the methods of Wilm *et al.* (Nature 379(6564):466-469 (1996)). Degenerate oligonucleotide primers can be synthesized based on the amino acid sequence of the purified protein or fragments of 5 the purified protein, and the corresponding DNA fragment can be amplified by polymerase chain reaction (PCR), as described in, e.g., *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989). The amplified DNA can be radiolabelled and used as a probe for screening a cDNA 10 library derived from N15 thymocyte mRNA in λzap express or other suitable vector. Corresponding clones can be isolated, DNA can obtained following *in vivo* excision, and the cloned insert can be sequenced in either or both orientations, such as by the methods described in *Current 15 Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), to identify the correct reading frame encoding a protein of the appropriate molecular weight. Using these or similar methods, the caspase protein(s) and the DNA encoding the protein can be isolated, sequenced and further 20 characterized.

Accordingly, the invention pertains to an isolated nucleotide sequence encoding the caspase enzyme. As appropriate, nucleic acid molecules of the present invention can be RNA, for example, mRNA, or DNA, such as 25 cDNA and genomic DNA. DNA molecules can be double-stranded or single-stranded; single stranded RNA or DNA can be either the coding, or sense, strand or the non-coding, or antisense, strand. Preferably, the nucleic acid molecule comprises at least about 25 nucleotides, more preferably at 30 least about 50 nucleotides, and even more preferably at least about 200 nucleotides. The nucleotide sequence can be only that which encodes at least a fragment of the amino acid sequence of the caspase protein; alternatively, the

nucleotide sequence can include at least a fragment of the caspase amino acid coding sequence along with additional non-coding sequences such as introns and non-coding 3' and 5' sequences (including regulatory sequences, for example).

5 Additionally, the nucleotide sequence can be fused to a marker sequence, for example, a sequence which encodes a polypeptide to assist in isolation or purification of the polypeptide. Such sequences include, but are not limited to, those which encode a glutathione-S-transferase (GST) fusion protein and those which encode a hemagglutin A (HA) peptide marker from influenza.

As used herein, an "isolated" gene or nucleotide sequence is intended to mean a gene or nucleotide sequence which is not flanked by nucleotide sequences which normally 15 (in nature) flank the gene or nucleotide sequence (as in genomic sequences) and/or has been completely or partially purified from other transcribed sequences (as in a cDNA or RNA library). Thus, an isolated gene or nucleotide sequence can include a gene or nucleotide sequence which is 20 synthesized chemically or by recombinant means. Thus, recombinant DNA contained in a vector are included in the definition of "isolated" as used herein. Also, isolated nucleotide sequences include recombinant DNA molecules in heterologous host cells, as well as partially or 25 substantially purified DNA molecules in solution. *In vivo* and *in vitro* RNA transcripts of the DNA molecules of the present invention are also encompassed by "isolated" nucleotide sequences. Such isolated nucleotide sequences are useful in the manufacture of the encoded protein, as 30 probes for isolating homologous sequences (e.g., from other mammalian species), for gene mapping (e.g., by *in situ* hybridization with chromosomes), or for detecting

expression of the caspase gene in tissue (e.g., human tissue), such as by Northern blot analysis.

The present invention also pertains to nucleotide sequences which are not necessarily found in nature but which do, in fact, encode the caspase. Thus, DNA molecules which comprise a sequence which is different from the naturally-occurring nucleotide sequence but which, due to the degeneracy of the genetic code, encode the caspase of the present invention are the subject of this invention.

5 The invention also encompasses variations of the nucleotide sequences of the invention, such as those encoding portions, analogues or derivatives of the caspase protein. Such variations can be naturally-occurring, such as in the case of allelic variation, or non-naturally-occurring, such as those induced by various mutagens and mutagenic processes. Included variations include, but are not limited to, addition, deletion and substitution of one or more nucleotides which can result in conservative or non-conservative amino acid changes, including additions and

10 deletions. Preferably, the nucleotide or amino acid variations are silent; that is, they do not alter the characteristics or activity of the caspase enzyme.

15

20

The invention described herein also relates to fragments of the isolated nucleic acid molecules described above. The term "fragment" is intended to encompass a portion of a nucleotide sequence described herein which is from at least about 25 contiguous nucleotides to at least about 50 contiguous nucleotides or longer in length; such fragments are useful as probes, e.g., for diagnostic methods and also as primers. Particularly preferred primers and probes selectively hybridize to the nucleic acid molecule encoding the caspase described herein. For

25

30

example, fragments which encode antigenic regions of the caspase protein described herein are useful.

The invention also pertains to nucleotide sequences which hybridize under low, medium or high stringency 5 hybridization conditions (e.g., for selective hybridization) to a portion of a nucleotide sequence described herein. Appropriate stringency conditions are known to those skilled in the art or can be found in standard texts such as *Current Protocols in Molecular 10 Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Such hybridizable nucleotide sequences are useful as probes and primers for diagnostic applications.

Accordingly, the invention pertains to nucleotide sequences which have a substantial identity with the 15 nucleotide sequences described herein; particularly preferred are nucleotide sequences which have at least about 90%, and more preferably at least about 95% identity with nucleotide sequences described herein. Particularly preferred in this instance are nucleotide sequences 20 encoding polypeptides having at least one activity of the novel caspase described herein. For example, preferred nucleotide sequences encoding a polypeptide having the same or similar biological activity as the novel caspase and nucleotide sequences encoding a polypeptide with the same 25 or similar immunogenic or antigenic properties as the novel caspase are within the scope of the invention. As used herein, activities of the caspase include, but are not limited to, catalytic activity, binding function, antigenic function and oligomerization function.

30 This invention also pertains to an isolated protein or polypeptide which is a novel caspase enzyme present in immature thymocytes and necessary for apoptosis. The caspase is characterized by its ability to be triggered by

TCR stimulation with peptide/MHC, anti-CD3 ϵ or other anti-TCR-specific monoclonal antibody, or corticosteroids in thymocytes. The caspase of the invention can be partially or substantially purified (e.g., purified to homogeneity), and/or is substantially free of other thymocyte proteins.

According to the invention, the amino acid sequence of the polypeptide can be that of the naturally-occurring protein or can comprise alterations therein. Such alterations include conservative or non-conservative amino acid substitutions, additions and deletions of one or more amino acids; however, such alterations should preserve at least one activity of the caspase, i.e., the altered or mutant protein should be an active derivative of the naturally-occurring protein. For example, the mutation(s) can preferably preserve the three dimensional configuration of the binding and/or catalytic site of the native protein. The presence or absence of caspase activity or activities can be determined by various functional assays as described herein. Moreover, amino acids which are essential for the function of the caspase can be identified by methods known in the art. Particularly useful methods include identification of conserved amino acids in the family or subfamily of caspases, site-directed mutagenesis and alanine-scanning mutagenesis (for example, Cunningham and Wells, *Science* 244:1081-1085 (1989)), crystallization and nuclear magnetic resonance. The altered polypeptides produced by these methods can be tested for particular biologic activities, including immunogenicity and antigenicity.

Specifically, appropriate amino acid alterations can be made on the basis of several criteria, including hydrophobicity, basic or acidic character, charge, polarity, size, the presence or absence of a functional

group (e.g., -SH or a glycosylation site), and aromatic character. Assignment of various amino acids to similar groups based on the properties above will be readily apparent to the skilled artisan; further appropriate amino acid changes can also be found in Bowie *et al.* (*Science* 247:1306-1310(1990)).

The caspase polypeptide can also be a fusion protein comprising all or a portion of the caspase amino acid sequence fused to an additional component. Additional components, such as radioisotopes and antigenic tags, can be selected to assist in the isolation or purification of the polypeptide or to extend the half life of the polypeptide; for example, a hexahistidine tag would permit ready purification by nickel chromatography. Furthermore, polypeptides of the present invention can be procaspases; procaspases are molecules which are cleaved to form an active tetramer (the caspase).

Also included in the invention are polypeptides which are at least about 40% identical to the novel caspase described herein. However, polypeptides exhibiting lower levels of identity are also useful, particular if they exhibit high, e.g., at least about 40%, identity over one or more particular domains of the protein. For example, polypeptides sharing high degrees of identity over domains necessary for particular activities, including binding and enzymatic activity, are included herein.

Polypeptides described herein can be isolated from naturally-occurring sources, chemically synthesized or recombinantly produced. Polypeptides or proteins of the present invention can be used as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using art-recognized methods.

The invention also provides expression vectors containing a nucleic acid sequence encoding a polypeptide which is a caspase present in immature thymocytes and necessary for apoptosis, operably linked to at least one regulatory sequence. Many such vectors are commercially available, and other suitable vectors can be readily prepared by the skilled artisan. "Operably linked" is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleic acid sequence. Regulatory sequences are art-recognized and are selected to produce a polypeptide which is a caspase. Accordingly, the term "regulatory sequence" includes promoters, enhancers, and other expression control elements which are described in Goeddel, 5 *Gene Expression Technology: Methods in Enzymology* 185, 15 Academic Press, San Diego, CA (1990). For example, the native regulatory sequences or regulatory sequences native to the transformed host cell can be employed. It should be understood that the design of the expression vector may 10 depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. For instance, the polypeptides of the present invention can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in 15 either prokaryotic cells, eukaryotic cells or both (see, for example, Broach, et al., *Experimental Manipulation of Gene Expression*, ed. M. Inouye (Academic Press, 1983) p. 83; *Molecular Cloning: A Laboratory Manual*, 2nd Ed., ed. 20 Sambrook et al. (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17). Typically, expression constructs will contain one or more selectable markers, including, but not limited to, the gene that encodes dihydrofolate reductase 25 and the genes that confer resistance to neomycin,

tetracycline, ampicillin, chloramphenicol, kanamycin and streptomycin resistance.

Prokaryotic and eukaryotic host cells transfected by the described vectors are also provided by this invention.

- 5 For instance, cells which can be transfected with the vectors of the present invention include, but are not limited to, bacterial cells such as *E. coli* (e.g., *E. coli* K12 strains, *Streptomyces*, *Pseudomonas*, *Serratia marcescens* and *Salmonella typhimurium*, insect cells (baculovirus),
10 including *Drosophila*, fungal cells, such as yeast cells, plant cells and mammalian cells, such as thymocytes, Chinese hamster ovary cells (CHO), and COS cells.

Thus, a nucleotide sequence derived from the cloning of the caspase described herein can be used to produce a recombinant form of the protein via microbial or eukaryotic cellular processes. Ligating the polynucleotide sequence into a gene construct, such as an expression vector, and transforming or transfecting into hosts, either eukaryotic (yeast, avian, insect, plant or mammalian) or prokaryotic (bacterial cells), are standard procedures used in producing other well known proteins. Similar procedures, or modifications thereof, can be employed to prepare recombinant proteins according to the present invention by microbial means or tissue-culture technology. Accordingly,
20 the invention pertains to the production of caspase proteins or polypeptides by recombinant technology.

The proteins and polypeptides of the present invention can be isolated or purified (e.g., to homogeneity) from recombinant cell culture by a variety of processes. These
30 include, but are not limited to, anion or cation exchange chromatography, ethanol precipitation, affinity chromatography and high performance liquid chromatography (HPLC). The particular method used will depend upon the

properties of the polypeptide and the selection of the host cell; appropriate methods will be readily apparent to those skilled in the art.

The present invention also relates to antibodies which bind a polypeptide which is a caspase present in immature thymocytes and necessary for apoptosis. For instance, polyclonal and monoclonal antibodies, including non-human and human antibodies, humanized antibodies, chimeric antibodies and antigen-binding fragments thereof (*Current Protocols in Immunology*, John Wiley & Sons, N.Y. (1994); EP Application 173,494 (Morrison); International Patent Application WO86/01533 (Neuberger); and U.S. Patent No. 5,225,539 (Winters)) which bind to the described caspase are within the scope of the invention. A mammal, such as a mouse, rat, hamster or rabbit, can be immunized with an immunogenic form of the caspase (e.g., the caspase or a peptide comprising an antigenic fragment of the caspase which is capable of eliciting an antibody response). Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. The protein or polypeptide can be administered in the presence of an adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibody.

Following immunization, anti-peptide antisera can be obtained, and if desired, polyclonal antibodies can be isolated from the serum. Monoclonal antibodies can also be produced by standard techniques which are well known in the art (Kohler and Milstein, *Nature* 256:495-497 (1975); Kozbar et al., *Immunology Today* 4:72 (1983); and Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss,

Inc., pp. 77-96 (1985)). The term "antibody" as used herein is intended to include fragments thereof, such as Fab and F(ab)₂. Antibodies described herein can be used to inhibit the activity of the caspase described herein, 5 particularly *in vitro* and in cell extracts, using methods known in the art. Additionally, such antibodies, in conjunction with a label, such as a radioactive label, can be used to assay for the presence of the expressed protein in a cell from, e.g., a tissue sample, and can be used in 10 an immunoabsorption process, such as an ELISA, to isolate the caspase. Tissue samples which can be assayed include human tissues, e.g., differentiated and non-differentiated cells. Examples include bone marrow, thymus, kidney, liver, brain, pancreas, fibroblasts and epithelium.

15 The present invention also pertains to pharmaceutical compositions comprising polypeptides described herein. For instance, a polypeptide or protein, or prodrug thereof, of the present invention can be formulated with a physiologically acceptable medium to prepare a 20 pharmaceutical composition. The particular physiological medium may include, but is not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions. The optimum concentration of the active ingredient(s) in the chosen 25 medium can be determined empirically, according to well known procedures, and will depend on the ultimate pharmaceutical formulation desired. Methods of introduction of exogenous peptides at the site of treatment include, but are not limited to, intradermal, 30 intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal. Other suitable methods of introduction can also include gene therapy, rechargeable or biodegradable devices and slow release polymeric devices.

The pharmaceutical compositions of this invention can also be administered as part of a combinatorial therapy with other agents.

The biochemistry of enzyme activation for other caspases has been discussed. In the case of the cell surface receptors CD95 and TNFR-1, cytoplasmic proteins which interact with the death domains of these transmembrane proteins have been identified: these include a TNFR1-associated death domain protein (TRADD) (Hsu et al., *Cell* 81:495-504 (1995)), a Fas-associated death domain protein (FADD) (Chinnaiyan et al., *Cell* 81:505-512 (1995); Boldin et al., *J. Biol. Chem.* 270:7795-7798 (1995)) and a receptor interacting protein (RIP) (Stranger et al., *Cell* 81:513-523 (1995)). FADD appears to function as a common signalling component of both TNFR-1 and CD95 (Chinnaiyan et al., *J. Biol. Chem.* 271:4961-4965 (1996b); Hsu et al., *Cell* 84:299-308 (1996a)), while TRADD mediates the interaction of TNFR-1 with FADD to induce apoptosis (Hsu et al., *Cell* 84:299-308 (1996a)). RIP appears to be involved in NFkB signalling (Hsu et al., *Immunity* 4:87-396 (1996b)). Upon oligomerization of CD95 or TNFR1, these cytoplasmic adapter molecules are recruited to the receptor cytoplasmic domain to form a death induced signalling complex or DISC (Kischkel et al., *EMBO J.* 14:5579-5588 (1995)). The recent cloning of FLICE (MACH, Mch5, caspase-8) (Muzio et al., *Cell* 85:817-827 (1996); Boldin et al. (1996); Fernandes-Alnemri et al. (1996)), also recruited to the DISC (Muzio et al. (1996)), links the cell surface death receptors directly to the initiation of a cascade of caspase activation: FLICE is recruited to the DISC and binds the Death Effector Domain (DED) of FADD. Upon receptor oligomerization, FLICE is cleaved to produce an active caspase. Thus, the initial step of caspase

activation after death receptor ligation has been defined for CD95 and TNFR1 (Muzio et al. (1996); Boldin et al. (1996)).

The anti-CD3 ϵ mAb-induced deletion of DP thymocytes was also blocked by zVADfmk in FTOC, suggesting that the same caspase involved in peptide/MHC-triggered death is active in this apoptotic pathway. However, cross-linking with this antibody did not induce deletion of DP thymocytes to the same extent as did peptide/MHC. It might be expected that crosslinking with anti-CD3 ϵ mAb would be more extensive than that induced by peptide/MHC, since there are two CD3 ϵ molecules per TCR and only one binding site for peptide/MHC. Furthermore, the mAb is bivalent, unlike the peptide/MHC, which is monovalent. The most likely explanation for this apparent paradox is that peptide/MHC-induced triggering may recruit other molecules, which act in synergy to provide a more potent death signal than that exclusively provided by crosslinking of TCR molecules by mAb.

For example, peptide/MHC binding recruits the CD4 or CD8 co-receptor with the attendant activation of protein tyrosine kinases including p56lck (reviewed in Rudd, *Immunol. Today* 11:400-406 (1990)). Furthermore, other signalling molecules have been shown to affect negative selection as discussed herein, although their roles in activation of the caspase remain to be determined. Certainly, there is precedent for the role of dual signalling within the T cell lineage: activation of resting peripheral T cells requires TCR crosslinking as well as co-stimulation through CD28 and its ligands, B7-1 and B7-2 (reviewed in Bluestone, J.A., *Immunity* 2:555-559 (1995)). Apoptosis of peripheral T cells involves second signals through Fas (CD95) and Fas-ligand, the expression

of which are regulated by TCR signalling (Crispe, I.N., *Immunity* 1:347-349 (1994)). Such dual signalling may also play a role in thymic selection; a second signal derived from thymic stroma along with the specificity-determining 5 TCR/peptide/MHC interaction may be required for negative selection (Page et al., *J. Immunol.* 151:1868-1880 (1993); Degermann et al., *J. Immunol.* 152:3254-3263 (1994); Punt et al., *J. Exp. Med.* 179:709-713 (1994); Lerner et al., *EMBO J.* 15:5876-5877 (1996)). For example, CD40L is induced on 10 activated thymocytes (Foy et al., *J. Exp. Med.* 182:1377-1388 (1995)) and CD40 is expressed in thymic stroma (Galy and Spits, *J. Immunol.* 149:775-782 (1992)). Injection of anti-CD40L mAb resulted in defective deletion 15 of thymocytes and inhibited medullary B7-2 expression (Foy et al. (1995)). CD40-CD40L interactions may affect negative selection, primarily by induction of new signalling molecules on the thymic stromal cell surface. Targeted disruption of CD30, another member of the TNF receptor family, produces a phenotype suggestive of a 20 defect in negative selection (Amakawa et al., *Cell* 84:551-562 (1996)). Thus, receptor-ligand interactions between thymocytes and stromal cells may induce one or more additional signals from the stroma important in the modulation of negative selection.

25 Glucocorticoids induce deletion of DP thymocytes in FTOC of C57BL/6 mice, and this deletion is blocked by zVADfmk. Rat thymocytes in suspension also undergo glucocorticoid-induced death which is blocked by zVADfmk (Fearnhead et al., *FEBS Lett.* 375:283-288 (1995)). This 30 death pathway is inhibited by *Bcl-2* in contrast to that of negative selection (reviewed in Yang and Korsmeyer (1996)). Since both forms of DP thymocyte depletion are blocked by zVADfmk, while *Bcl-2* selectively affects glucocorticoid-

induced deletion but does not alter negative selection, it appears that the glucocorticoid and antigen/MHC pathways share some, but not all, components of the death pathway. Nevertheless, they converge to a common death effector mechanism involving a thymic caspase.

In the immune system, apoptosis plays a critical role in the development and maintenance of mature lymphocytes. In peripheral T-cells, CD95 and its ligand are induced during the development of an immune response (Ju et al., 10 *Nature* 373:444-448 (1995)); thus apoptosis mediated by the CD95 pathway serves to limit and control T-cell activation. The CD95 pathway has been relatively well characterized as described above and involves, at a minimum, activation of caspase-1, caspase-3, caspase-7 and caspase-8. Activation 15 of target cell caspase-3, caspase-8 and *ICH-3* by cytotoxic T cells, as noted above, is also an important element of immune effector function within the peripheral lymphoid organs. The present findings add the process of negative selection to the expanding role of caspases in immune 20 regulation.

It is a long-standing enigma as to how events which induce negative selection and death in immature thymocytes induce activation and accompanying proliferation in mature T cells (Ramarli et al., *Proc. Natl. Acad. Sci. USA* 25 84:8598-8602 (1987); Kappler et al., *Cell* 49:273-230 (1987)). Hence, the developmental stage of the T cell determines its response to a particular stimulus. In TCR transgenic mice, antigenic peptides which activate peripheral T cells to proliferate trigger depletion of the 30 immature thymocytes bearing the identical TCR (Fowlkes and Pardoll (1989)). Most TCR transgenic models in which deletion by peptide antigen has been examined demonstrate that the deletion involves the immature DP thymocytes

(Murphy *et al.* (1990); Vasquez *et al.*, *J. Exp. Med.* 175:1307-1316 (1992); Sebzda *et al.* (1994); Ashton-Rickardt *et al.*, *Cell* 76:651-663 (1994a); Hogquist *et al.*, *Cell* 76:17-27 (1994)). The presence of the peptide/MHC activated caspase in the DP thymocyte subset further identifies this population as the one in which negative selection is operative.

Interactions between peptide/MHC expressing antigen presenting cells and DP thymocytes is also required for positive selection. Thymocyte expressing TCRs which productively bind MHC-peptide ligands on thymic stromal cells selectively receive signals to mature into functional single positive (SP) cells (Berg *et al.*, *Cell* 60:1043-1053 (1990); Koller *et al.*, *Science* 248:1227-1230 (1990)). MHC-bound cognate peptides which interact with TCRs with high affinity induce negative selection, while peptides containing a single amino acid substitution, which lowers the affinity for the TCR without affecting MHC binding (altered peptide ligands, APL's), induce positive selection (Hogquist *et al.* (1994); Jameson *et al.*, *Nature* 369:750-752 (1994); Spain *et al.*, *J. Immunol.* 152:1709-1717 (1994); Hogquist *et al.*, *Immunity* 3:79-86 (1995)). In addition, cognate peptides, when present at a very low concentration, can induce positive rather than negative selection (Sebzda *et al.* (1994); Ashton-Rickardt *et al.*, *Cell* 76:651-663 (1994a)), supporting the notion of an avidity model to explain thymic selection outcome (Ashton-Rickardt *et al.*, *Immunol. Today* 15:362-366 (1994b)). Some studies suggest that negative and positive selection are separated spatially and temporally, and that positive selection precedes negative (Laufer *et al.*, *Nature* 383:81-85 (1996)). Others have suggested that both forms of selection may occur concurrently but that only a single outcome results.

The question of what determines the fate of a thymocyte facing the pathways of positive versus negative selection remains unclear. Certainly, the strength of a signal induced by the extent of receptor crosslinking can 5 vary and be modulated by ligand affinity and receptor occupancy (Meuer et al., *Proc. Natl. Acad. Sci. USA* 81:1509-1513 (1984); Maruyama et al., *Cell* 48:343-350 (1987)). For example, the activity of the IL2 and IL2R promoters are differentially induced, depending on the 10 degree of TCR crosslinking in Jurkat T cells (Maruyama et al. (1987)). Both Ca²⁺ flux and protein phosphorylation triggered by cell surface receptors are variably affected by the degree of TCR crosslinking (Alcover et al., *Proc. Natl. Acad. Sci. USA* 83:2614-2618 (1986); Koyasu et al., 15 *Proc. Natl. Acad. Sci. USA* 91:6693-6697 (1994)). Such events regulate many cellular processes; thus, the different intensities of interaction between a TCR and its ligand may induce very different outcomes on the same thymocytes. In this way, it may be possible for the thymus 20 to filter out those autoreactive T cells with highest TCR affinity for self-MHC peptide, while retaining thymocytes with weak, but nevertheless self-MHC restricted, specificities. This process of thymocyte "editing" is probably dependent on more parameters than the TCR-pMHC 25 interaction itself, and, therefore, influenced by co-receptor interactions as well. The latter offers an explanation for why the level of co-receptor expression alters the outcome of selection (Robey et al., *Cell* 69:1089-1096 (1992)).

30 Recently, using N15 TCRtg RAG-2-/- H-2b mice, a population of DP TCR-high thymocytes which is resistant to deletion by peptide antigen was identified. Presumably, these thymocytes have already been positively selected by

an endogenous peptide antigen (APL) prior to VSV8 injection and are on their way to becoming mature CD8 SP T cells. If the activation of a caspase is the mechanism by which negative selection operates, then these cells must be
5 unable to activate the thymic caspase upon TCR engagement with VSV8. It may be that the caspase mRNA is expressed only at a limited stage of development, and these cells no longer express the caspase gene. Alternatively, these cells may produce an inhibitor of the thymic caspase, such
10 as a *Bcl-2*-like molecule, which inactivates the thymic caspase. In addition, a molecule which provides a second signal(s) necessary for thymic selection as discussed above may no longer be expressed on the DP thymocytes. Once the genetic and biochemical details of the negative selection
15 pathway are defined, it should be possible to determine which of these mechanisms accounts for the escape of the DP TCR-high thymocytes from peptide/MHC induced death.

Accordingly, the work described herein has many uses. For example, it is apparent from this work that apoptosis
20 can be inhibited in lymphocytes, particularly immature thymocytes, by inhibiting the activity of the caspase implicated herein in programmed cell death. As used herein, "inhibition" is intended to encompass any reduction in the occurrence of apoptosis, including complete
25 abolition of apoptosis. Inhibition of caspase activity can be brought about by decreasing either the amount of caspase enzyme present, the enzymatic activity of the caspase enzyme, or both. For example, the activity of the caspase enzyme described herein can be inhibited by a
30 tripeptide or tetrapeptide having an amino acid sequence of VAD, YVAD and DEVD, for example, and wherein the tetrapeptide or tripeptide is linked to a fluoromethylketone, an acyloxymethylketone, a

chlormethylketone, a diazomethylketone, an aldehyde, a semicarbazone, a nitrile or an epoxide. These compounds reversibly or irreversibly react with the active site cysteine thiol of the cysteine protease. A compound of 5 this type, or a pro-drug thereof, can be administered to an individual to inhibit the activity of the caspase implicated in cell death, thereby inhibiting apoptosis.

By inhibiting apoptosis as described above, the down regulation of lymphocytes, particularly thymocytes, can be 10 prevented or inhibited; thus, DP thymocytes are prevented from self-destruction. This results in a T cell receptor population with an increased proportion of autoreactive T cells; that is, there is an increased occurrence of T cells which have specificity for the host animal's own cells. 15 This is particularly advantageous when it is desirable to generate an immune response against the host's own cells (an autoimmune response), such as, for example, in the case of tumor growth and cancers such as leukemia and melanomas. This technology is especially useful for preparing animal 20 models having depleted T cell populations and animal models for autoimmune disease. The invention also pertains to methods of enhancing an immune response against an antigen in a mammal by administering to the mammal an effective amount of an agent which inhibits the activity of the 25 caspase along with the selected antigen. In a particular embodiment, the antigen is a cancer antigen.

Many uses of the technology will be apparent to the skilled artisan. For example, an appropriate animal, e.g., a mammal, can be immunized with a selected self-antigen 30 (e.g., tumor antigen or other protein present on the surface of the targeted cell or tissue) concurrently with treatment with a caspase-inhibitor; thus, T cells are generated which recognize the self-antigen and are not

destroyed by the caspase activity. These self-recognizing T cells have the capacity to mount an immune response to the self-antigen in the animal, thereby destroying the targeted cell or tissue.

5 This invention pertains to methods of enhancing the activity of the caspase enzyme, thereby enhancing apoptosis of self-recognizing T cells. As used herein, "enhancing" is intended to encompass any increase in caspase activity, whether brought about by increase in the activity of the 10 enzyme itself, or by increase in the amount of enzyme or enzyme mimic present, or both. As used herein, "enzyme mimic" is intended to mean an agent which has the same activity as (or mimics) the caspase and includes fragments or other variants of the caspase as described above.

15 Disorders can be treated by altering the specific programmed cell death of autoreactive T cells which are responsible for the autoimmune disorder. For example, the invention pertains to methods of enhancing apoptosis in immature thymocytes by contacting the thymocytes, or active 20 derivatives or fragments thereof, with an agent which enhances caspase activity. The caspase activity can be enhanced in an animal to produce a depleted T cell population; this is particularly advantageous in instances where the animal's T cells have developed harmful 25 specificities, e.g., rheumatoid arthritis and juvenile diabetes melitis. In such situations, the naturally- occurring caspase of the harmful cell is triggered with an appropriate agent, e.g., an antigen or drug or agent which causes or enhances caspase activity, to cause apoptotic 30 death of the cell. It is also contemplated that cells, particularly thymocytes, which, in nature, lack caspase and/or procaspase expression and activity can be engineered to express the caspase and/or procaspase of the invention

by gene therapy methods. For example, DNA encoding the caspase or procaspase protein, or an active fragment or derivative thereof, can be introduced into an expression vector, such as a viral vector, and the vector can be
5 introduced into appropriate cells which lack caspase and/or procaspase expression in an animal. In such a method, an immature thymocyte population can be engineered to inducibly or constitutively express active caspase, eliminating the need for the cell to convert inactive
10 procaspase to caspase to induce apoptosis. In a preferred embodiment, the vector is delivered to the bone marrow, for example as described in Corey *et al.* (*Science* 244:1275-1281 (1989)).

Enhancement or inhibition of apoptosis of self-
15 recognizing lymphocytes as described above can be useful in the treatment of acute and chronic immune and autoimmune diseases, including chronic hepatitis, systemic lupus erythematosus, rheumatoid arthritis, thyroidosis, scleroderma, diabetes mellitus, Graves' disease, Beschet's disease and graft versus host disease (graft rejection).
20

Thus, the present invention can be used to treat a range of disorders in addition to the above immune and autoimmune diseases; for example, various infections, including, but not limited to, sepsis syndrome, cachexia,
25 circulatory collapse and shock resulting from acute or chronic bacterial infection, acute and chronic parasitic and/or infectious diseases from bacterial, viral or fungal sources, such as a HIV, AIDS (including symptoms of
30 cachexia, autoimmune disorders, AIDS dementia complex and infections) can be treated. Inflammatory diseases, such as chronic inflammatory pathologies and vascular inflammatory pathologies, including chronic inflammatory pathologies such as sarcoidosis, chronic inflammatory bowel disease,

ulcerative colitis, and Crohn's disease and vascular inflammatory pathologies, such as, but not limited to, disseminated intravascular coagulation, atherosclerosis, and Kawasaki's pathology are also suitable for treatment by 5 methods described herein.

Treatable disorders also include neurodegenerative diseases, including, but not limited to, demyelinating diseases, such as multiple sclerosis and acute transverse myelitis; extrapyramidal and cerebellar disorders' such as 10 lesions of the corticospinal system; disorders of the basal ganglia or cerebellar disorders; hyperkinetic movement disorders such as Huntington's Chorea and senile chorea; drug-induced movement disorders, such as those induced by drugs which block CNS dopamine receptors; hypokinetic 15 movement disorders, such as Parkinson's disease; Progressive supranucleo palsy; Cerebellar and Spinocerebellar Disorders, such as astructural lesions of the cerebellum; spinocerebellar degenerations (spinal ataxia, Friedreich's ataxia, cerebellar cortical 20 degenerations, multiple systems degenerations (Mencel, Dejerine-Thomas, Shi-Drager, and MachadoJoseph)); and systemic disorders (Refsum's disease, abetalipoproteinemia, ataxia, telangiectasia, and mitochondrial multi.system disorder); demyelinating core disorders, such as multiple 25 sclerosis, acute transverse myelitis; disorders of the motor unit, such as neurogenic muscular atrophies (anterior horn cell degeneration, such as amyotrophic lateral sclerosis, infantile spinal muscular atrophy and juvenile spinal muscular atrophy); Alzheimer's disease; Down's 30 Syndrome in middle age; Diffuse Lewy body disease; Senile Dementia of Lewy body type; Wernicke-Korsakoff syndrome; chronic alcoholism; Creutzfeldt-Jakob disease; Subacute

sclerosing panencephalitis, Hallerorden-Spatz disease; and Dementia pugilistica, or any subset thereof.

It is also recognized that malignant pathologies involving tumors or other malignancies, such as, but not limited to leukemias (acute, chronic myelocytic, chronic lymphocytic and/or myelodyspastic syndrome); lymphomas (Hodgkin's and non-Hodgkin's lymphomas, such as malignant lymphomas (Burkitt's lymphoma or Mycosis fungoides)); carcinomas (such as colon carcinoma) and metastases thereof; cancer-related angiogenesis; infantile hemangiomas; alcohol-induced hepatitis. Ocular neovascularization, psoriasis, duodenal ulcers, angiogenesis of the female reproductive tract, can also be treated.

The present invention also relates to an assay for identifying agents which alter the activity of the caspase implicated in lymphocyte, particularly thymocyte, apoptosis. For example, the caspase or procaspase, or an active fragment or derivative thereof, can be contacted with a caspase substrate in the presence of an agent to be tested, and the level of lymphocyte apoptosis can be assessed; alternatively, the level of lymphocyte apoptosis can be assessed and compared with the corresponding level in a control in the absence of the agent to be tested. The caspase can be contacted directly with the substrate in the presence of the agent to be tested, or a thymocyte or cell lysate thereof comprising the caspase or procaspase can be contacted with the agent to be tested. Enhancement of apoptosis, or an increase in the level of apoptosis relative to a control, indicates that the agent is an agonist of caspase activity. Examples of caspase enhancing agents or agonists include, for example, compounds or enzymes which will convert procaspase to caspase, enhance

oligomerization of the caspase, or an enzymatically active fragment or variant thereof, a sequence which encodes one of the above in an appropriate expression vector or a compound which will enhance the expression of the
5 procaspase or caspase in the cell. Similarly, inhibition of apoptosis, or a decrease in the level of apoptosis relative to a control, indicates that the agent is an antagonist of caspase activity. Examples of caspase antagonists include, for example, compounds or enzymes
10 which will inhibit conversion of procaspase to caspase, inhibit oligomerization of the caspase, or a variant or caspase without enzymatic activity which can inhibit (e.g., by competitive inhibition) caspase activity, decrease or eliminate expression of active procaspase or caspase in the
15 cell.

The present invention also relates to agents identified by the assay described above. Agents identified by the assay described herein may enhance (e.g., prolong or increase) or inhibit (e.g., shorten or decrease) the
20 activity of the caspase implicated in apoptosis. Agents which can inhibit caspase activity can be selected from tripeptide or tetrapeptide having an amino acid sequence of VAD, YVAD, or DEVD, and wherein the tetrapeptide or tripeptide is linked to a fluoromethylketone or an
25 acyloxymethylketone, or a prodrug thereof.

The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention. The teachings of all references cited herein are hereby
30 incorporated herein by reference.

EXAMPLES

MATERIALS AND METHODS

T CELL RECEPTOR CONSTRUCTS

The full-length N15 α and N15 β cDNAs were isolated by 5 oligonucleotide priming from total RNA of the N15 CTL clone and subcloned into the pCRII vector (Invitrogen). To engineer N15 constructs for the creation of transgenic mice, TCR shuttle vectors were used (kindly provided by M. Davis). A PCR product encoding the N15 V α 8-J α 5 was 10 generated from 50 ng of psTCR_{N15Lz α} using 1.64 μ g of each of the following oligonucleotides:

5' -CTCGAGACCTGTGTGGATTAAAAACCTCTGATTCTGGTTGCTTTCTGTTCC
AAGCAGGGGTGAGAGGAGACTCCGTGACCCAGACAGAACAGGCCTG-3' (SEQ ID NO:
5); and
15 5' -GCGGCCGCTTGGGCCAAGAAACTGTCATCAAACGTACGTGCTATAACCTTCAGTC
TGGTACCTGCTCC-3' (SEQ ID NO: 6).

Only 10 cycles of PCR (1' at 94°C, 1' at 60°C and 1' at 72°C) were performed on the relative large amount of template DNA to minimize the probability of mutation. The 20 resulting 448bp fragment was digested with XhoI and NotI and inserted into the similarly digested TCRA shuttle vector. The N15 TCR β expression vector was generated by ligation of a 423bp ClaI/NotI digested PCR product derived from the psTCR_{N15Lz β} (same PCR conditions as described above 25 for N15 α) encoding N15 V β 5.2-D β 2-J β 2,6 into the ClaI/NotI sites of the TCR β shuttle vector. The following oligonucleotides were used to amplify the N15 β fragment:
5' -ATCGATTCCCCTTCTTGCTGTATTACATCTTGTGTTCTCTTAGGATC
AGCAGATTCTGGGGTTGTCCAGTCTCCAAG-3' (SEQ ID NO: 7); and
30 5' -GC GGCCGCACGTGGGGCCCCAGCTCACCTAAAACCGTGAGCCTGGTGCCGGGACC
G-3' (SEQ ID NO: 8).

All the oligonucleotides contained restriction sites in the 5' end. The cDNA inserts encoding VJ and V(D)J

sequences in N15 α and β shuttle constructs respectively were sequenced and found to be error-free.

TRANSGENIC MICE

The N15 α and β shuttle constructs were digested with 5 Clai/SaII or PvuI/SaII, respectively, leaving the bacterial vector sequences attached to the T cell receptor gene. These DNAs were co-injected into [SJL x C57BL/6]F2 or RAG-2^{-/-} [43] fertilized eggs and implanted into foster mothers. Resulting progeny mice were screened for integration of the 10 N15 α and β chain DNA by Southern blot analysis of tail DNA and by FACS analysis of N15 β chain expression in peripheral blood nucleated cells. Four transgenic founders were identified, two for each background. Progeny of line L2 (RAG-2^{-/-} background), backcrossed for 2-5 generations into 15 C57BL/6-RAG-2^{-/-} mice, were used for the experiments described below. RAG-2^{-/-} and β RAG-2^{-/-} backcrossed for 6-10 generations into C57BL/6, as well as the N15tg lines, were maintained and bred under sterile barrier standard conditions in the animal facility of Dana Farber Cancer 20 Institute.

C57BL/6 mice were purchased from Taconic (Germantown, NY) For injection of anti-CD3 ϵ specific hamster anti-mouse mAb 145-2C11 (2C11), the anti-CD3 ϵ mAb (American Type Culture Collection, Rockville, MD) was purified by standard 25 procedures (Coligan et al., Current Protocols in Immunology, John Wiley & Sons (1994)), and 200 mg was injected intraperitoneally in PBS. For injection of peptide, 24 mg of VSV8 (RGYVYQGL; SEQ ID NO: 9) or SEV9 (FAPGNYPAL) was injected in 100 ml PBS into the tail vein 30 of the mouse.

FETAL THYMIC ORGAN CULTURE (FTOC)

Fetuses of C57BL/6 mice were dissected at day 14.5 of pregnancy, with the day of the vaginal plug counted as day 1. Fetuses of N15 TCRtg RAG-2^{-/-} H-2^b mice were dissected 5 at day 15.5. Fetal lobes were removed and cultured in 6-well Transwell dishes (Costar, Kennebunk, ME) using 1.6 ml of complete DMEM-10 (Life Technologies, Gaithersburg, MD) as described in Coligan, et al. (1994). The samples were incubated in a humidified atmosphere with 5% CO₂ for 4-5 10 days at 37°C and treated with specific reagents as described. For harvesting, lobes were ground between frosted glass slides in PBS-1% BSA, washed, and used for flow cytometric analysis (FACS analysis).

FLOW CYTOMETRIC ANALYSIS

15 Monoclonal antibodies used were R-phycoerythrin (PE) labeled anti-CD4 (H129.19) and Red613 labeled anti-CD8 (53-6.7) (GIBCO BRL, Grand Island, NY). Harvested thymocytes were washed and stained for 30 minutes with anti-CD4 and anti-CD8 mAbs. Flow cytometric analysis was 20 performed on a FACScan (Becton Dickinson, San Jose, CA). Samples were gated on live cells based on forward and side scatter parameters. Data on 10,000 events per sample were collected in list mode using FACScan Research software and analyzed using LYSYSII software (Becton Dickinson, San 25 Jose, CA).

SYNTHESIS OF PEPTIDE-BASED INHIBITORS AND RELATED COMPOUNDS

N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, b-methyl ester (zVADfmk) was from Enzyme System Products (Dublin, CA). Biotin-YVADamk was purchased from Amersham 30 Life Science (Arlington Heights, IL).

N-[Biotinylaspartyl(b-t-butyl ester)glutamyl(g-t-butyl ester)valine was prepared by solid phase synthesis on a 2-chlorotrityl resin (Barlos *et al.*, *Intl. J. Pept. Protein Res.* 37:513-520 (1991)) using an HOAt/HATU coupling protocol (Carpino *et al.*, *J. Chem. Soc., Chem. Commun.* 201-203 (1994)). Acyloxyketone, N-Z-aspartic acid[(2,6-dimethylbenzoyl)oxy]-methyl ketone, b-t-butyl ester, was prepared according to the method of Krantz (Krantz *et al.*, *Biochemistry* 30:4678-4687 (1991)) from the corresponding bromomethyl ketone (Dolle *et al.*, *J. Med. Chem.* 37:563-564 (1994a)) and deprotected by hydrogenolysis (Dolle *et al.*, *J. Med. Chem.* 37:3863-3866 (1994b)) to afford aspartic acid[(2,6-dimethylbenzoyl)oxy]methyl ketone, b-t-butyl ester, as the HCl salt. Coupling of this amine with N-[biotinylaspartyl(b-t-butyl ester)glutamyl(g-t-butyl ester)valine was carried out by HOAt/HATU-mediated solution phase synthesis (Carpino (1993)) as follows:

N-(Biotinylaspartylglutamylvalinyl)aspartic acid
[(2,6-Dimethylbenzoyl)oxy]methyl Ketone [Biotin-DEVDamk]
Diisopropylethyl amine (110 μ L, 0.645 mmol) was added to an ice-cooled solution of N-[biotinylaspartyl(b-t-butyl ester)glutamyl(g-t-butyl ester)valine (150 mg, 0.215 mmol), aspartic acid[(2,6-dimethylbenzoyl)oxy]methyl ketone, b-t-butyl ester hydrochloride (80 mg, 0.215 mmol), HOAt (30 mg, 0.215 mmol) and HATU (125 mg, 0.33 mmol) in DMF (1 mL), and the resulting solution was allowed to warm to room temperature. After stirring overnight, the mixture was concentrated under reduced pressure, and the residue was chromatographed on a silica gel column eluting with chloroform followed by chloroform/methanol (20:1). The material was further purified by a second silica gel column

eluting with chloroform followed by a gradient of chloroform/acetone/methanol (4:1:0) - (2:1:0) - (2:1:1%) to produce 60 mg of the coupled product as a colorless solid. The *tert*-butyl esters were removed by treating this
5 material with a mixture of TFA/DCM (3:2, 2.5 mL) at room temperature for 3 hours. Concentration under reduced pressure, followed by repeated treatment (3X) with toluene (0.5 mL) and concentration, produced 50 mg (quant) of the desired product as a light yellow solid. Recrystallization
10 from methanol gave pure product which was shown by reverse phase HPLC (C18) analysis to consist of a 1:1 mixture of diastereoisomers. Similar to the observation of Thornberry (Thornberry *et al.*, *Biochemistry* 33:3934-3940 (1994)), 1H NMR analysis indicated the diastereomeric center to be at
15 the P₁ aspartic acid a-carbon. ES mass spectrum (M-) m/e 847 [M-H], 869 [M-H+Na]; ES mass spectrum (M+) m/e 849 [M+H], 871 [M+Na].

N-(Z-Valinylalanyl)aspartic acid methyl ketone, b-methyl ester [z-VADmk]

20 N-(Z-Valinylalanyl)aspartic acid methyl ketone, b-methyl ester [z-VADmk] was prepared as a diastereomeric mixture (racemic at aspartyl a-carbon) from N-(Z-valinylalanyl)aspartic acid, b-methyl ester (standard solid phase coupling) by a Dakin-West reaction with acetic
25 anhydride, triethylamine and DMAP at 50°C (Steglich and Hofle., 1969). FAB mass spectrum (M+) m/e 450 [M+H].

IMMUNOHISTOLOGIC ANALYSIS AND TUNEL ASSAY

Fetal thymuses were embedded in O.C.T. compound (Miles, Elkhart, IN) on dry ice. Four mm sections were
30 prepared and subsequently stored at -80°C. For the TUNEL assay, frozen tissue sections were fixed in 3% buffered

formalin for 10 minutes at room temperature. After washing with PBS, sections were fixed again in ethanol/acetic acid (2:1) for 10 minutes at -20°C. Endogenous peroxidase activity was blocked by covering the sections with 0.5% H₂O₂ for 20 minutes at room temperature. The sections were rinsed with PBS and immersed in TdT buffer (30 mM Trizma base, pH 7.2, 140 mM sodium cacodylate, 1 mM cobalt chloride). The sections were incubated with 2-4 mM biotinylated dUTP (Boehringer Mannheim, Mannheim, Germany) and 5-10 U TdT (Promega, Madison, WI) in 25 ml TdT buffer in a humid atmosphere at 37°C for 2 hours. The reaction was terminated by transferring the slides to TB buffer (300 mM NaCl, 30 mM Na citrate) for 15 minutes. After a PBS rinse, sections were incubated with 2% BSA for 10 minutes, rinsed in PBS for 5 minutes, incubated with avidin/biotinylated-peroxidase complex (Dako, Santa Barbara, CA) diluted 1:100 in PBS for 30 minutes, washed in PBS and developed with 3-amino-9-ethylcarbazole (Aldrich, Milwaukee, WI). Sections were lightly counterstained with Meyer's hematoxin (Gavrieli et al., *J. Cell. Biol.* 119:493-501 (1992)).

Two-color immunohistochemical analysis was performed as previously described (Mizoguchi et al., *J. Exp. Med.* 183:847-856 (1996)). Briefly, 4 mm thick specimens were fixed in acetone for 7 minutes, air dried, and incubated with purified anti-CD4 antibody (clone L3T4, PharMingen, San Diego, CA) for 1 hour at room temperature. Specimens were incubated for 30 minutes with 0.3% hydrogen peroxide in PBS to block endogenous peroxidase activity. Endogenous biotin was blocked by sequential incubations with avidin-D (Vector, Burlingame, CA) and d-biotin (Sigma, St. Louis, MO). For detection, biotinylated rabbit anti-rat Ig (Vector) was used, followed by an optimal dilution of

avidin-biotinylated peroxidase complex (Dako). The specimens were developed in a solution of 3-amino-9-ethylcarbazole (Aldrich) and the reaction stopped by dipping in distilled water for 5 minutes and washing in 5 PBS (pH 7.4) for 10 minutes. The specimens were then incubated with biotin-DEVDamk peptide at room temperature for 1 hour, followed by incubation with ABC-alkaline phosphatase reagent (Vector, Burlingame, CA) for 30 minutes. After 15 minutes of development with alkaline phosphatase substrate Kit III (Vector) and 1M levamisole 10 (Sigma, St. Louis, MO), the specimens were postfixed with 2% paraformaldehyde and mounted with glycergel (Dako, Carpinteria, CA).

PREPARATION OF THYMIC LYSATES AND WESTERN BLOT ANALYSIS

15 Thymocyte suspensions were prepared as described above for FACS. Cells were washed three times in PBS-1% BSA, and lysates were prepared as previously described (Thornberry et al. (1994)). Briefly, thymocytes were resuspended at 1 $\times 10^8$ /ml in hypotonic buffer containing 25 mM Hepes, pH 20 7.5, 5 mM MgCl₂, 1 mM EGTA, 1 mM PMSF, 10 mg/ml leupeptin and 10 mg/ml pepstatin. After 20 minutes on ice, cells were broken with 20 strokes in a tight-fitting Dounce homogenizer. Cell lysates were clarified by centrifugation 25 at 2000 rpm in an eppendorf microfuge for 10 minutes, followed by an 8 minute spin in a Beckman airfuge at 100,000 g. The lysates were dialyzed overnight at 4°C against 20 mM Tris, pH 7.8, 2 mM DTT and 0.1% CHAPS. Cell lysates were aliquoted and stored at -80°C. Recombinant Yama and Mch2a were prepared as described (Orth et al., J. 30 Biol. Chem. 271:20977-20980 (1996)).

For Western blot analysis, cell lysate equivalent to 2 $\times 10^6$ cells was incubated with the indicated additions for

15 minutes at 25°C. Non-reducing sample buffer was added, samples boiled for 7 minutes and run on 12.5% SDS-PAGE under nonreducing conditions. Gels were blotted onto nitrocellulose and the membranes blocked overnight in PBS, 5 3% BSA, 0.1% Tween-20. The filter was washed twice for 10 minutes in PBS, 0.1% BSA, 0.1% Tween-20 and incubated 2 hours at room temperature with a 1:10,000 dilution of streptavidin-conjugated horseradish peroxidase (ICN, Costa Mesa, CA) in PBS, 0.1% BSA, 0.1% Tween-20. The filter was 10 washed 6 times for 10 minutes with 50 mM Tris-HCl, pH 7.5, 0.25% gelatin, 0.05% Tween-20, 150 mM NaCl, 5 mM EDTA, then washed once in PBS and developed by ECL (Renaissance, NEN, Boston, MA).

RESULTS

15 CASPASE INHIBITION IN FTOC PREVENTS DP THYMOCYTE DELETION MEDIATED BY ANTI-CD3 ϵ mAb

Prior studies utilizing the anti-CD3 ϵ specific hamster anti-mouse mAb 145-2C11 (2C11) have shown that DP thymocytes are susceptible to undergo apoptotic cell death 20 upon exposure to 2C11 in FTOC (Smith et al., *Nature* 337:181-184 (1989)) or upon parenteral *in vivo* administration (Shi et al., *J. Immunol.* 146:3340-3346 (1991)). Therefore, the effect of a caspase inhibitor on anti-CD3 ϵ -induced deletion of the CD4+CD8+ DP thymocytes 25 was first analyzed using C57BL/6 animals. Fetal thymocytes were dissected on day 14.5 of pregnancy and cultured in transwells for 4 days. On day 4, additions were made to the FTOCs, including 2C11 mAb in the presence or absence of 100 mM zVADfmk, an irreversible inhibitor of cysteine 30 proteases, and thymocytes were harvested 18 hours later.

Upon 2C11 mAb addition, the percent of DP thymocytes is reduced from 66% in the control culture to 37% in the

culture treated for 18 hours with 200 mg/ml 2C11 mAb. Moreover, the deletion of these DP thymocytes is inhibited by a 2-hour preincubation with zVADfmk. zVADfmk alone does not alter the percentage of DP thymocytes nor does dimethyl sulfoxide (DMSO), the additive used to solubilize zVADfmk, affect the deletion of DP thymocytes. A control hamster anti-mouse mAb, H28 (Becker *et al.*, *Cell* 58:911-921 (1989)), directed against a segment of the TCR α chain which is inaccessible on intact thymocytes, has no effect on the FTOC.

zVADfmk INHIBITS GLUCOCORTICOID-INDUCED DP THYMOCYTE DEATH IN FTOC

DP thymocytes are exquisitely sensitive to pharmacological doses of glucocorticoids *in vivo* (Wyllie, *Nature* 284:555-556 (1980)). The rapid thymic involution known to result from stress is a consequence, in large part, of endogenous release of steroids as well. To determine whether caspase inhibition blocks DP thymocyte apoptosis induced by corticosteroids, the effects of dexamethasone on DP thymocyte survival in FTOC were examined in the presence or absence of zVADfmk.

Dexamethasone at 0.1 mM reduces the percentage of DP thymocytes from 74% to 19%. A 2-hour pretreatment with 100 mM zVADfmk protects the CD4+CD8+ population from dexamethasone-induced death. The inhibition of deletion is specific to the zVADfmk reagent and not due to the DMSO solvent. These results demonstrate that two well-known inducers of CD4+CD8+ DP thymocyte death, anti-CD3 ϵ mAb and glucocorticoids, are blocked by inhibition of cysteine protease activity.

zVADfmk PROTECTS DP THYMOCYTES FROM ANTIGEN-INDUCED
DELETION IN N15 TCR tg RAG-2^{-/-} H-2^b MICE

Given that negative selection of thymocytes *in vivo* is antigen-driven, the effect of zVADfmk on specific peptide-induced deletion of DP thymocytes in FTOC derived from TCR tg mice was tested. To this end, the N15 TCR tg mouse was employed; this mouse bears a class I MHC-restricted TCR and recognizes the vesicular stomatitis virus nuclear protein octapeptide VSV8 in the context of H-2 Kb. The VSV8 peptide interacts with Kb with high affinity such that a single *in vitro* or *in vivo* exposure efficiently loads the Kb molecules in the thymus of these animals. The animals were additionally constructed on a RAG-2^{-/-} background (Shinkai et al., *Cell* 68:855-867 (1992)), thereby guaranteeing exclusive expression of this TCR on the surface of T lineage cells. In these experiments, fetuses were dissected at day 15.5, as it was observed that the development of N15 tg RAG-2^{-/-} animals was slightly slower than that of the corresponding wild type C57BL/6 animals.

After five additional days of FTOC, 60% of N15 TCR tg RAG-2^{-/-} H-2b thymocytes were DP and 24% were CD8+ SP thymocytes (Figure 4A). Addition of 10-5 M VSV8 peptide to the N15 FTOCs 18 hours prior to analysis results in massive depletion of CD4+CD8+ DP thymocytes with a reduction from 60% to 2% (Figure 4B). zVADfmk completely blocks this antigen-induced deletion (Figure 4C). Importantly, zVADmk, a compound identical to zVADfmk (Figure 1) except for the absence of the fluoride atom which is required for the irreversible inhibition of caspases, has no effect on the antigen-induced deletion of DP thymocytes (Figure 4D). Hence, inhibition of enzymatic function is a prerequisite for protecting DP thymocytes from deletion by specific

antigen. Exposure of the FTOC to the DMSO solvent prior to VSV8 treatment has no effect (Figure 4E). The depletion of DP thymocytes is specifically induced by the VSV8 peptide; addition to the FTOC of an equivalent amount of the
5 unrelated SEV9 Sendai virus-derived peptide, which binds to Kb with a comparable affinity to that of VSV8 but which is not recognized by the N15 TCR, does not result in thymocyte death (Figure 4F).

HISTOLOGICAL ANALYSIS OF ANTIGEN-INDUCED APOPTOSIS IN FTOC
10 OF N15 TCR tg RAG-2^{-/-} H-2^b MICE: BLOCKADE OF CELL DEATH BY
zVADfmk

Negative selection results in apoptosis of DP thymocytes as judged by morphological criteria or induction of DNA fragmentation as analyzed by gel electrophoresis or
15 TUNEL assay (Murphy et al. (1990); Surh and Sprent, *Nature* 372:100-103 (1994)). Apoptosis in this TCR tg system was confirmed to be induced by the VSV8 peptide in N15 FTOC using a terminal deoxynucleotidyl transferase (TdT) assay on histological sections. This method exploits the fact
20 that apoptosis results in DNA cleavage, the ends of which serve as a substrate for the TdT enzyme, allowing cells undergoing death to be labeled with biotinylated dUTP. Sections were prepared from fetal thymic lobes, cultured as described above, and treated for 4 hours with 10-5M VSV8
25 peptide with either no pretreatment or a 1-hour pretreatment with zVADfmk or zVADmk. This early time point was chosen for the characterization, as it was previously observed that after overnight exposure to VSV8, dying DP thymocytes from adult animals were already removed by an
30 efficient process involving the non-lymphoid stromal components of the thymus. The effective removal of corpses

has been previously described in both tg and non-tg thymuses as well (Surh and Sprent, (1994)).

VSV8 treatment resulted in an obvious increase in the number of TdT positive cells as compared to the control culture which was not exposed to the VSV8 peptide.

Pretreatment with zVADfmk prior to VSV8 addition reduces the number of TdT+ cells to that of the control. In contrast, zVADmk pretreated cultures which were exposed to VSV8 had levels of TdT positive cells similar to cultures treated with VSV8 alone. Table 1 shows a quantitative tabulation of the immunohistological results for three N15 tg RAG-2^{-/-} H-2^b FTOCs and a littermate control non-tg RAG-2^{-/-} FTOC. Thus, the depletion of DP thymocytes in the N15 TCR tg RAG-2^{-/-} H-2^b FTOC is blocked specifically with a cysteine protease inhibitor, and this inhibition correlates with a reduction in the number of apoptotic cells as determined by TdT assays. This is the first demonstration that inhibition of a caspase(s) prevents apoptotic cell death induced by antigen triggering of the TCR on immature DP thymocytes.

Table 1: Quantitation of cell death in FTOC by TUNEL assay

TdT positive cellsmm²

<u>Treatment</u>	<u>N15tq #1</u>	<u>N15tq#2</u>	<u>N15tq#3</u>	<u>non-tq</u>
Control	7	28	7	1
VSV8	429	456	441	9
zVADfmk + VSV8	6	1	2	6
zVADmk + VSV8	360	525	461	Not Determined

TCR-TRIGGERED ACTIVATION OF CASPASE(S) : A BIOCHEMICAL ANALYSIS

Although the above results clearly demonstrate that the zVADfmk cysteine protease inhibitor can block antigen-triggered cell death, it remained to be determined whether TCR ligation specifically activates a cysteine protease. Members of the caspase family exist as proenzymes which are cleaved by an activation step to give rise to ~20KD and ~12KD subunits (reviewed in Henkart, *Immunity* 4:195-201 (1996)). The heterodimeric subunits then associate to form a tetramer. Because the tetramer but not the inactive proenzyme binds the substrate, a biochemical assay was developed to examine the state of caspases in thymuses of unstimulated or *in vivo* VSV8-triggered N15 tg mice. To this end, several possible substrates were tested, including biotin-YVADamk and biotin-DEVDamk (Figure 1). Because the biotin-DEVDamk substrate appears to have the highest affinity for the thymic caspase, only this data is presented.

N15 transgenic RAG-2^{-/-} H-2^d mice were injected in the tail vein with PBS, 24 mg VSV8 or control SEV9 peptide, and extracts were prepared from the thymocytes of these adult mice 2 hours after injection. Lysate equivalent to 2 x 10⁶ thymocytes was incubated with or without 2 mM biotin-DEVDamk, which binds irreversibly to caspases with varying rates depending on the specific protease. Subsequently, the treated lysates were analyzed by 12.5% SDS-PAGE and blotted onto nitrocellulose. The membranes were then incubated with streptavidin horseradish peroxidase and developed by ECL. A band of approximately 17 kD is induced in the 2-hour VSV8 treated thymocytes (Figure 2A). This band is not found in lysates from thymuses of PBS or SEV9 injected animals, and is not

detected in thymic lysates without prior incubation with biotin-DEVDamk (Figure 2A). As expected, purified, recombinant Yama/caspase-3 and Mch2a (caspase-6) proteases bind the biotin-DEVDamk substrate in this assay (Figure 5 2B).

The above functional studies, utilizing zVADfmk and the biochemical analysis with biotin-DEVDamk, collectively show that cysteine proteases are activated during antigen-induced negative selection in the thymus. Whether 10 the same caspase(s) interacts with both of these inhibitors remains to be determined. This possibility was tested by competitive inhibition analysis wherein the above thymic lysates were first preincubated with up to 1000-fold molar excess of zVADfmk prior to addition of the biotin-DEVDamk. 15 If both substrate inhibitors bound to the same enzyme, then the non-biotin labeled zVADfmk would block the ability of biotin-DEVDamk to bind to the activated thymic caspase and hence, eliminate detection of the ~17kD subunit by streptavidin horseradish peroxidase. Alternatively, if 20 these inhibitors bound to different enzymes, then there would be no change in the appearance of the caspase band as detected by biotin-DEVDamk.

Figure 2C shows that if the thymic lysates are incubated first with zVADfmk at molar concentrations 25 ranging from 1000- to 100-fold that of the biotin-DEVDamk substrate, the ~17kD band is no longer detectable by Western blot analysis. In contrast, at lower zVADfmk:biotin-DEVDamk ratios (10:1 or 1:1), the biotin-DEVDamk substrate is bound by the TCR-triggered 30 cysteine protease and therefore detected as a ~17kD biotinylated inhibitor-enzyme complex. Thus, the irreversible binding of zVADfmk, which blocks VSV8-induced depletion of the DP thymocytes in FTOC, competes with the

biotin-DEVDamk substrate for binding to the same ~17kD band. This result links the antigen-induced negative selection of thymocytes, as measured by depletion of DP thymocytes in FTOC, to the appearance of an activated cysteine protease detectable in the thymuses of mice undergoing negative selection. Figure 2D shows that while 100-fold molar excess of zVADfmk blocks binding of the biotin-DEVDamk substrate to the antigen-activated cysteine protease, the same excess of zVADmk does not block this interaction. This finding is consistent with the observation that zVADmk fails to block antigen-induced depletion of the DP thymocytes in FTOC.

LOCALIZATION OF ACTIVATED CASPASE TO TCR-TRIGGERED CORTICAL THYMOCYTES IN N15 tg RAG-2^{-/-} H-2^b FETAL AND ADULT MICE

To localize the activated caspase within the thymus of fetal and adult N15 tg RAG-/- H-2b mice, two-color immunohistological analysis was performed using biotin-DEVDamk and anti-CD4 mAb. In the N15 RAG^{-/-} H-2^b mice, CD4 staining is essentially limited to the DP thymocytes because the N15 TCR is class I MHC-restricted, resulting in positive selection of CD8+ SP cells exclusively. The majority of thymocytes demonstrate CD4 staining (red/brown), consistent with the large percentage of DP thymocytes present in the thymus of these animals. Staining with biotin-DEVDamk (blue) is negative. In contrast, 4 hours after treatment with VSV8, the CD4 staining became patchy, and the morphology of the CD4 cells was altered, with less discrete cell boundaries. In addition, there is widespread biotin-DEVDamk staining throughout the cortex, indicative of antigen-induced activation of a thymic caspase. Consistent with the biochemical analysis, this activation is blocked by

pretreatment with zVADfmk, but not with pretreatment with zVADmk.

The same staining pattern is evident in adult N15 tg RAG-2^{-/-} H-2^b mice. Thymic sections of N15 tg RAG-2^{-/-} H-2^b animals were positive for anti-CD4 reactivity and negative for that of biotin-DEVDamk. However, 4 hours following tail vein injection of VSV8 peptide, the thymic section demonstrated widespread biotin-DEVDamk staining, as well as the same alterations in anti-CD4 reactivity as seen in the VSV8-treated FTOCs. PBS injection does not induce damage to the CD4+ thymocytes or detectable activation of the cysteine protease. Thus, deletion of DP thymocytes occurs through antigen-stimulated activation of a cysteine protease in both FTOC and adult mice, and this activity localizes to the thymocytes themselves.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims:

CLAIMS

We claim:

1. An isolated caspase or procaspase expressed in immature thymocytes, or an active derivative or fragment thereof, wherein said caspase is necessary for apoptosis.
2. An isolated caspase according to Claim 1, wherein said caspase is characterized by its ability to be triggered by TCR stimulation with peptide/MHC, anti-CD3 ϵ or other anti-TCR-specific monoclonal antibody, or corticosteroids in thymocytes.
3. The isolated caspase or procaspase of Claim 1, wherein said caspase is a fragment possessing caspase activity.
4. The isolated caspase or procaspase of Claim 1, wherein said caspase or procaspase is a derivative possessing substantial sequence identity with the endogenous caspase or procaspase.
5. The isolated caspase or procaspase of Claim 1, wherein said caspase or procaspase has the same amino acid sequence as the endogenous caspase or procaspase.
6. The isolated caspase or procaspase of Claim 5, wherein said caspase or procaspase is isolated from immature thymocytes.
7. The isolated caspase or procaspase of Claim 6, wherein said caspase or procaspase is purified to homogeneity.

8. The isolated caspase or procaspase of Claim 6, wherein said caspase or procaspase is substantially free of other thymocyte proteins.
9. An isolated nucleic acid molecule which encodes a caspase or procaspase expressed in immature thymocytes and necessary for apoptosis, or an active derivative or fragment thereof.
10. An isolated nucleic acid molecule according to Claim 9, wherein the caspase is characterized by its ability to be triggered by TCR stimulation with peptide/MHC, anti-CD3 ϵ or other anti-TCR-specific monoclonal antibody, or corticosteroids in thymocytes.
11. The isolated nucleic acid molecule of Claim 9, wherein said molecule comprises at least about 25 nucleotides.
12. The isolated nucleic acid molecule of Claim 9, wherein said molecule comprises at least about 50 nucleotides.
13. The isolated nucleic acid molecule of Claim 9, wherein said molecule comprises at least about 200 nucleotides.
14. The isolated nucleic acid molecule of Claim 9, wherein the caspase or procaspase is a derivative possessing substantial sequence identity with the endogenous caspase or procaspase.
15. The isolated nucleic acid molecule of Claim 9, wherein said caspase or procaspase has the same amino acid sequence as the endogenous caspase or procaspase.

16. The isolated nucleic acid molecule Claim 15, wherein said nucleic acid molecule has the same nucleotide sequence as the endogenous gene encoding the caspase or procaspase.
- 5 17. A DNA construct comprising the isolated nucleic acid molecule of Claim 9 operatively linked to a regulatory sequence.
- 10 18. A DNA construct comprising the isolated nucleic acid molecule of Claim 15 operatively linked to a regulatory sequence.
19. A DNA construct comprising the isolated nucleic acid molecule of Claim 16 operatively linked to a regulatory sequence.
- 15 20. A recombinant host cell comprising the isolated nucleic acid molecule of Claim 9 operatively linked to a regulatory sequence.
21. A recombinant host cell comprising the isolated nucleic acid molecule of Claim 15 operatively linked to a regulatory sequence.
- 20 22. A recombinant host cell comprising the isolated nucleic acid molecule of Claim 16 operatively linked to a regulatory sequence.
23. The recombinant host cell of Claim 22 wherein said cell is selected from the group consisting of bacterial cells, fungal cells, plant cells, insect cells and mammalian cells.

24. A method for preparing a caspase or procaspase expressed in immature thymocytes, or an active derivative or fragment thereof, wherein said caspase is necessary for apoptosis, comprising culturing the recombinant host cell of Claim 20.
- 5
25. A method according to Claim 24, wherein the caspase is characterized by its ability to be triggered by TCR stimulation with peptide/MHC, anti-CD3ε or other anti-TCR-specific monoclonal antibody, or corticosteroids in thymocytes
- 10
26. An antibody, or an antigen-binding fragment thereof, which selectively binds to the caspase or procaspase according to Claim 1, or an active derivative or fragment thereof.
- 15 27. The antibody according to Claim 26, wherein said antibody is a monoclonal antibody.
- 20
28. A method for assaying the presence of a caspase or procaspase according to Claim 1 in a cell, comprising contacting said cell with an antibody which specifically binds to the caspase or procaspase.
29. The method of Claim 28, wherein said cell is in a tissue sample.
30. A method of identifying an agent which inhibits the caspase according to Claim 1, comprising the steps of:
- 25 (a) contacting the caspase, or an active derivative or fragment thereof, with a

- caspase substrate in the presence of
the agent; and
- (b) identifying inhibition of caspase activity.
31. An agent which inhibits caspase activity identified
5 according to the method of Claim 30.
32. A method of identifying an agent which inhibits the
caspase according to Claim 1, comprising the steps of:
10 (a) contacting a thymocyte or a cell lysate
thereof comprising the caspase or
procaspase, with the agent; and
(b) identifying inhibition of caspase activity.
33. An agent which inhibits caspase activity identified
according to the method of Claim 32.
34. A method of inhibiting the caspase according to Claim
15 1, comprising contacting said caspase with an agent
that inhibits the activity of the caspase.
35. A method of inhibiting apoptosis in a lymphocyte
comprising contacting said lymphocyte with an agent
which inhibits the caspase according to Claim 1.
- 20 36. A method according to Claim 35, wherein said apoptosis
is induced by a member of the group consisting of an
antigen, a corticosteroid and anti-CD3 ϵ monoclonal
antibody.
- 25 37. A method according to Claim 35, wherein the lymphocyte
is an immature thymocyte.

38. A method according to Claim 35, wherein the agent is a tripeptide or tetrapeptide having an amino acid sequence selected from the group consisting of VAD, YVAD, and DEVD, and wherein the tetrapeptide or tripeptide is linked to a compound selected from the group consisting of fluoromethylketone, acyloxymethylketone, chlormethylketone, diazomethylketone, aldehydes, semicarbazones, nitriles and epoxides.
- 5
- 10 39. A method of inhibiting apoptosis in an immature thymocyte comprising contacting said thymocyte with an agent according to Claim 31.
40. A method of inhibiting apoptosis in an immature thymocyte comprising contacting said thymocyte with an agent according to Claim 33.
- 15
- 20 41. A method of identifying an agent which enhances the caspase according to Claim 1, comprising the steps of:
- (a) contacting the caspase, or an active derivative or fragment thereof, with a caspase substrate in the presence of the agent; and
- (b) identifying enhancement of caspase activity.
42. An agent which enhances caspase activity identified according to the method of Claim 41.
- 25 43. A method of identifying an agent which enhances the caspase according to Claim 1, comprising the steps of:

- (a) contacting a thymocyte or a cell lysate thereof comprising the caspase or procaspase, with the agent; and
 - (b) identifying enhancement of caspase activity.
- 5 44. An agent which enhances caspase activity identified according to the method of Claim 43.
45. A method of enhancing the caspase according to Claim 1, comprising contacting said caspase with an agent that enhances the activity of the caspase.
- 10 46. A method of enhancing apoptosis in a lymphocyte comprising contacting said lymphocyte with an agent which enhances the caspase according to Claim 1.
47. A method according to Claim 46, wherein the lymphocyte is an immature thymocyte.
- 15 48. A method of enhancing apoptosis in an immature thymocyte comprising contacting said thymocyte with an agent according to Claim 42.
49. A method of treating an autoimmune disease in a mammal comprising administering to the mammal an effective amount of an agent which enhances the activity of the caspase according to Claim 1.
- 20 50. The method of Claim 49, wherein the autoimmune disease is chronic hepatitis or diabetes mellitus.

51. A method of enhancing an immune response against an antigen in a mammal comprising administering to the mammal an effective amount of an agent which inhibits the activity of the caspase according to Claim 1 and an antigen.
52. A method of treating a cancer in a mammal comprising administering to the mammal an effective amount of an agent which inhibits the activity of the caspase according to Claim 1 and a cancer antigen.

THYMOCYTE CASPASE ACTIVITY AND NEGATIVE SELECTION

ABSTRACT OF THE INVENTION

Work described herein shows that T cell receptor triggering by peptide/MHC ligands activates a caspase in thymocytes, including CD4+CD8+ double positive thymocytes, resulting in their death. Methods of inhibiting apoptosis in thymocytes are described, as well as assays for identifying an agent which alters the activity of the caspase are described.

RECEIVED
MAY 10 2002
U.S. PATENT AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

THYMOCYTE CASPASE ACTIVITY AND NEGATIVE SELECTION

the specification of which (check one)

is attached hereto.

was filed on _____ as United States Application Number or PCT International Application Serial No. _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority
Not
Claim

(Number)	(Country)	(Day/Month/Year filed)	[]
(Number)	(Country)	(Day/Month/Year filed)	[]
(Number)	(Country)	(Day/Month/Year filed)	[]

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

08/802,474 (Application Serial No.)	2/18/97 (Filing date)	Pending (Status, patented, pending, abandoned)
----------------------------------------	--------------------------	---------------------------------------------------

(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
--------------------------	---------------	----------------------------------------

(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
--------------------------	---------------	----------------------------------------

(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
--------------------------	---------------	----------------------------------------

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorney(s) and/or agent(s) to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states:

David E. Brook	Reg. No. 22,592	Thomas O. Hoover	Reg. No. 32,470
James M. Smith	Reg. No. 28,043	Alice O. Carroll	Reg. No. 33,542
Leo R. Reynolds	Reg. No. 20,884	N. Scott Pierce	Reg. No. 34,900
Patricia Granahan	Reg. No. 32,227	Richard A. Wise	Reg. No. 18,041
Mary Lou Wakimura	Reg. No. 31,804	Lisa M. Warren	Reg. No. 41,368
Carolyn S. Elmore	Reg. No. 37,567	Helen E. Wendler	Reg. No. 37,964

all of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02173;

and _____

Send correspondence to: Carolyn S. Elmore
Hamilton, Brook, Smith & Reynolds, P.C.
Two Militia Drive
Lexington, Massachusetts 02173
Direct telephone calls to: Carolyn S. Elmore

(617) 861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole

or first inventor Ellis Reinherz

Inventor's

Signature _____ Date _____

Residence 113 South Great Road

Lincoln, Massachusetts 01773

Citizenship USA

Post Office Address Same as above

Full name of second joint

inventor, if any Linda Clayton

Inventor's

Signature _____ Date _____

Residence 48 Cedarwood Road

Jamaica Plain, Massachusetts 02130

Citizenship USA

Post Office Address Same as above

Full name of third joint

inventor, if any Timothy D. Ocain

Inventor's

Signature _____ Date _____

Residence 45 Indian Head Road

Framingham, MA 01701

Citizenship USA

Post Office Address Same as above

Full name of third joint

inventor, if any Raymond J. Patch

Inventor's

Signature _____ Date _____


Residence 16 Emily Road

Framingham, MA 01701


Citizenship USA

Post Office Address Same as above


DFCI522A DEC LMW32




zVADfmk



zVADmk



Biotin-DEVDamk



Biotin-YVADamk

Figure 1

Figure 2A




Figure 2B




Figure 2C





Figure 2D






Figure 3




Figure 4A

Figure 4B

Figure 4C

Figure 4D

Figure 4E

Figure 4F